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ABSTRACT 
Measurement of systemic immunoglobulin (Ig) concentrations in horses and 
camelids is important for early and accurate diagnosis of immunodeficiencies in order to 
provide proper medical intervention. As a consequence, there is a demand for up-to-
date, economic, rapid and precise diagnostic assays for Igs. Accordingly, multiple 
methods for the evaluation of Ig concentrations have been evaluated in equine and 
camelid species, each with particular advantages and disadvantages. 
Fourier-transform infrared (FTIR) spectroscopy has recently emerged as a 
powerful diagnostic tool for the quantitative characterization of biological fluids in 
human and veterinary medicine. In particular, FTIR spectroscopy has proven to be an 
accurate, economical and reagent-free method for immunoglobulin G (IgG) quantitation 
in horses. Further research to investigate its potential application in the quantitation of 
other equine Ig isotypes and IgG subclasses is warranted. Additionally, as rapid 
quantitative assays for the measurement of camelid serum IgG are limited, further work 
to assess the use of FTIR spectroscopy in this area is desirable.   
 The objectives of this thesis were: (1) to develop an FTIR-based assay for the 
measurement of IgG concentrations in alpaca serum and to compare its performance to 
that of the radial immunodiffusion (RID) assay, and (2) to develop FTIR-based assays for 
the measurement IgGa, IgGb, IgG(T), IgA, and IgM for equine plasma using ELISA assays 
as reference tests. 
The first objective of this thesis was achieved by performing RID IgG assays and 
collecting FTIR spectra for 175 alpaca serum samples. A FTIR-based assay was built using 
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partial least squares regression to convert the spectroscopic data into quantitative IgG 
values which were compared to the RID results. Correlation coefficients and scatter 
plots indicated good to excellent levels of agreement between the assays. The results 
suggest that FTIR spectroscopy may be a useful method for IgG measurement in alpaca 
serum.  
For the second objective, IgGa, IgGb, IgG(T), IgA, and IgM concentrations were 
determined by ELISA assays and FTIR spectra were collected for 100 equine plasma 
samples. The spectra were randomly divided into training and prediction sets. The 
training set was used to build a calibration model for each Ig isotype or IgG subclass 
using partial least squares regression, while the prediction set was used to test the 
performance of the developed models. Pearson correlation coefficients and scatter 
plots displayed moderate to good agreement between FTIR and ELISA IgGb assay results 
but poor overall agreement for IgGa, IgG(T), IgA and IgM assay results. As well, 
significant differences were noted between the ELISA results of this study and the 
reviewed studies from the published literature. At present, a FTIR spectroscopic 
approach is an inaccurate technique for the measurement of Ig isotypes or IgG 
subclasses in equine plasma.  
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GENERAL INTRODUCTION 
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1.1. Immunology in camelid and equine species 
1.1.1. Protection from infectious agents 
The mammalian body is able to defend itself against invading pathogens in three 
main ways: anatomical barriers, the innate immune system and the adaptive immune 
system (1-3). Physical and chemical barriers are considered the body’s first line of 
defence and include the skin and epithelial layers, secretions such as tears, saliva, sweat 
and mucous, and the normal endogenous flora and pH of the skin and urinary, 
respiratory and gastrointestinal tracts (4). Often these anatomical barriers are effective 
at protecting the body, despite a constant barrage from microorganisms within the 
environment. However, with enough time and persistence they can be overcome by 
invading pathogens, and the immune system is then activated (3-5). 
In addition to anatomical barriers, the body is protected from infectious agents 
by a large number of effector cells and molecules which collectively form the immune 
system (4, 5). This system can be divided into innate and adaptive branches, each of 
which has their own specialized cells and mechanisms to eliminate infection (2, 4, 6).  
1.1.2. Innate immune system 
The innate immune system is present in all multicellular organisms and is 
considered the next line of defence against invading pathogens after anatomical barriers 
are breached (4, 6, 7). It is rapid acting and possesses a variety of resistance 
mechanisms to block, recognize and destroy invading microorganisms as they attempt 
to establish infection in the body (4-7). The main elements of the innate immune system 
can be divided into cellular and humoral aspects (5). Cellular components include the 
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mononuclear (macrophages and monocytes) and polymorphonuclear (neutrophils, 
basophils and eosinophils) phagocytes, dendritic cells and natural killer cells; each of 
which plays a unique role in innate immunity (2, 3, 5, 8). For example, macrophages are 
well known for their ability to ingest and destroy invading microbes through the process 
of phagocytosis and they have a key role in cell recruitment to an infection site through 
the release of chemoattractant cytokines (5). On the other hand, dendritic cells are 
known for their ability to initiate the adaptive immune response through antigen 
presentation and T cell stimulation (4, 5).   
Humoral components of the innate immune system include numerous 
antimicrobial peptides and molecules, as well as complement and acute phase proteins 
(1, 3, 5). As with the cellular components, each of the humoral elements of innate 
immunity plays a specific role in host defense (5). For instance, the enzyme lysozyme 
can destroy gram positive and negative bacterial cells walls through the hydrolysis of 
glycosidic bonds. The glycoprotein lactoferrin alters the mobility of certain bacteria, 
such as Pseudomonas, thereby decreasing their pathogenicity. C-reactive proteins will 
bind to the capsule of Streptococcus spp. to further enhance their detection and 
destruction by cellular components of innate immunity (4, 5). Ultimately, regardless of 
their classification as cellular or humoral, all cells, proteins and molecules of the innate 
immune system work together to initiate or participate in a variety of host defense 
mechanisms including pathogen recognition, phagocytosis, inflammation, complement 
activation, cytokine production and antigen presentation (2, 4, 5, 7, 8).     
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 The ability of the innate immune system to identify and respond to invading 
microbes relies heavily on the identification of particular microbial structures which 
have been conserved across a broad spectrum of microorganisms (5, 7, 8). These 
structures, termed pathogen-associated molecular patterns (PAMPs), are a highly 
conserved components of the microbe not easily altered by mutation (3, 5). With time, 
host organisms have developed a set of pattern-recognition receptors (PRRs) on their 
cells (8). These PRRs are capable of identifying various PAMPs and this recognition leads 
to cytokine production and the activation of numerous immune responses (7). Some of 
the most well-known examples of PAMPs include lipopolysaccharides and techoic acids 
(common components of gram negative, and gram positive bacterial cell walls, 
respectively) and double-stranded RNA expressed by viruses (3, 4, 7). Common 
examples of PRRs include mannose binding lectin and toll-like receptors (of which there 
are numerous forms) (3, 4, 8). 
This is only a brief introduction of the innate immune system, which is a large, 
complex and expansive subject. Full details regarding innate immunity are beyond the 
scope of this thesis.  
1.1.3. Adaptive immune system 
1.1.3.1. Overview 
Any invading foreign substances (e.g. bacteria, viruses, fungi, protozoa or 
helminths) capable of initiating an immune response are termed antigens (1). Two 
distinct classes of antigens capable of activating the acquired immune system have been 
identified. The first are microorganisms which exist extracellularly and proliferate in the 
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tissues and extracellular fluids.  The second class includes invading organisms which 
have the ability to exist within the host’s cells (i.e. intracellular organisms such as viruses 
or specific bacteria) (1, 9). Due to the immense diversity of potential antigens, the 
adaptive immune system is extraordinarily complex and can be divided into two major 
branches: cell-mediated and humoral immunity; each responsible for identifying and 
facilitating the destruction of specific pathogens (1, 3). Additionally, the complex nature 
of the adaptive immune system is governed by two main cell types, T and B 
lymphocytes. T lymphocytes mature in the thymus and have roles in both cellular and 
humoral immunity (6). Certain T lymphocytes, such as cytotoxic T cells, are responsible 
for cell-mediated immunity and their primary function is to kill cells infected by 
intracellular pathogens (4, 6). Others, like helper T cells, assist in the activation of 
antigen-stimulated B cells or can activate macrophages to increase their efficiency at 
destroying engulfed pathogens (4, 10). Finally, there are regulatory T cells which modify 
the immune response through suppression of other lymphocytes (4, 6). B lymphocytes 
mature in the bone marrow and are responsible for directing the humoral immune 
responses in the body (1, 4).  
The adaptive immune system may take several days or weeks to become fully 
activated, yet is extraordinarily effective at eliminating infection (4). Adaptive immunity 
evolved approximately 400 million years ago and is present only in vertebrate species 
(6). It is characterized by the response of lymphocytes to specific antigens and the 
subsequent development of immunological memory (3, 4, 6). The concept of true 
immunological memory is an adaptive immune response intended to confer protective 
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immunity to the host in the event of re-exposure to an antigen (11). Following an initial 
response to and elimination of an infectious agent, memory B and T cells are generated 
in the body. Subsequent encounters with the same antigen will stimulate these memory 
cells, resulting in a more rapid and enhanced immunological response to a second 
exposure of the offending agent (3, 4, 11).  
Another important feature of the adaptive immune system is the ability of 
immune cells to distinguish between the body’s own cells and unwanted pathogens (4). 
Both B and T lymphocytes are able to recognize and respond to antigens due to the 
presence of highly specific antigen receptors on their cell surfaces (4). Each individual 
lymphocyte has receptors with a single antigen specificity and, collectively, the 
numerous lymphocytes of the body generate a large repertoire of antigen receptors 
which enable the immune system to identify and respond to almost any antigen it may 
be challenged with (3, 4).  
A vast array of diverse antigen receptors are generated during B and T 
lymphocyte development where specific gene segments undergo irreversible DNA 
recombination (4, 6). Three types of gene segments are known (V, D and J) with multiple 
copies of each present in germline DNA. Only one of each type of gene segment is 
joined together during recombination to form a lymphocyte receptor specific for a 
particular antigen (6, 12, 13).  Once a functional receptor is successfully produced during 
the VDJ recombination process, further rearrangement is blocked, ensuring each 
lymphocyte expresses only one specific antigen receptor (4). Through this process of 
VDJ recombination, just a few hundred gene segments are capable of combining in a 
7 
 
variety of ways to generate millions of different lymphocyte antigen receptors. 
Junctional diversity further amplifies the lymphocyte receptor diversity through 
nucleotide insertions or deletions during the process of gene segment joining (4, 12). As 
a result, individuals encompass a large repertoire of B and T lymphocytes, each with a 
unique antigen binding capability (12, 13). B lymphocytes are able to recognize various 
conformations of antigen such as proteins, carbohydrates or simple chemical groups, 
whereas most T cell receptors are only capable of recognizing peptides bound to specific 
glycoproteins called major histocompatibility complex molecules (3, 6).  
Due to the random nature of gene recombination, it is inevitable that certain 
self-reactive T and B lymphocytes will be generated, i.e. have receptors which respond 
to the body’s own self-antigens (3, 14). As a result, the adaptive immune system has 
developed several mechanisms to identify and eliminate self-reactive lymphocytes 
before damage to host cells occur (4, 15). The first of these mechanisms is central 
tolerance. With this method, immature lymphocytes which recognize antigens in the 
central lymphoid organs will receive a negative signal resulting in their inactivation 
and/or death via apoptosis (3, 4, 14).  Similar to this, but occurring in the secondary 
lymphoid organs (e.g. spleen, lymph nodes, etc.), is the mechanism of peripheral 
tolerance (3).  This method relies on the co-stimulatory signals generated by the innate 
immune system during an infection which are essential for activation of adaptive 
immunity. In the absence of infection and these signals, a mature lymphocyte which 
encounters a self-antigen in the peripheral lymphoid organs will receive a negative, 
inactivating signal and mount no immune response (4). A final mechanism to assist the 
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immune system in discriminating between self and non-self is the tolerization of 
lymphocytes to self-antigens (3, 4). Many self-antigens are expressed abundantly by the 
cells of the body and therefore provide strong, constant signals to mature lymphocytes 
receptors. As a result, lymphocytes become tolerant of these antigens and do not 
respond by activation (4). Conversely, when a pathogen enters the body, their antigen 
concentration will increase rapidly as they replicate in the early stages of infection. This 
leads to the activation of naïve, mature lymphocytes as they respond to the sudden 
increase in antigen receptor signals (1, 4). Under normal physiological conditions, these 
mechanisms are adequate to allow lymphocytes to distinguish between self and non-
self antigens, however, they are not infallible and failure to make this distinction can 
lead to the development of autoimmune disease (3, 4).  
1.1.3.2. Humoral immunity 
1.1.3.2.1. Antibody overview 
Antibodies are glycoproteins, found in the tissues and fluid components of the 
body (4).  They belong to a family of proteins called immunoglobulins (Igs) which are an 
essential component of the adaptive immune system. Immunoglobulins exist within the 
body in one of two forms: as membrane bound molecules on a B cell (B cell receptors, 
[BCRs]) or as soluble, secreted molecules (antibodies) (12). Each B cell has 
approximately 200,000 to 500,000 identical BCRs on its cell surface which allow that 
particular cell to respond to one specific antigen. These receptors are able to bind to an 
immense array of chemical structures including glycoproteins, polysaccharides, whole 
virus particles or bacterial cells through recognition of epitopes on the antigen’s surface 
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(1). Certain microbial antigens are capable of directly activating B cells while others 
require the assistance of helper T cells for B cell activation (4).  
When a B cell becomes activated, it will respond by proliferating and 
differentiating into either plasma B cells (also known as effector B cells) or memory B 
cells (3). Plasma B cells develop in the lymph nodes and spleen from where they travel 
via the blood stream or lymphatic system to become distributed throughout the body 
(16). They function to produce and secrete large amounts of antibody, up to 10,000 
molecules per second, all with antigen binding specificity identical to that of the parent 
B cell (1, 16). Memory B cells, as previously mentioned, are one of the key components 
of immunological memory, capable of providing enhanced, rapid immune responses 
upon re-exposure to their original inciting antigen (4). 
1.1.3.2.2. Antibody structure 
Antibodies are Y-shaped proteins with molecular weights ranging from 160-180 
kDa (1). The top potion (or ‘arms’) of the molecule is known as the variable region (V 
region) as it contains highly diverse antigen binding sites. In contrast, the area of the 
antibody which has a relatively unchanging amino acid sequence (the ‘stem’ of the Y) is 
known as the constant region (C region) (4, 13). The C region of an antibody molecule 
exists in one of five main forms, each designed to engage different effector functions of 
the immune system (4, 12). 
Each antibody is composed of 4 peptide chains: 2 identical heavy chains (H 
chains) and 2 identical light chains (L chains). The light and heavy chains are linked 
together by disulfide bonds which also chemically bind the heavy chains to each other, 
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giving the antibody molecule a characteristic ‘Y’ shape (4, 13). The stem of the Y-shaped 
antibody consists only of heavy chains while the two identical arms are comprised of 
both heavy and light chains. The antigen binding sites are located at the tips of the arms 
which are joined to the stem via a flexible hinge region (4).  
1.1.3.2.3. Antibody classification and function 
In mammals, there are 2 distinct types of light chains, kappa (Κ) and lambda (λ), 
which are differentiated by their amino acid sequences, yet are functionally identical 
(13). Different species of mammals have varying ratios of Κ and λ light chains, however 
the reason for this is unknown and no functional differences have been found between 
antibodies with different ratios of Κ and λ light chains (4, 13).  
The C region of an Ig consists only of heavy chains and it is these chains which 
will determine the name and effector function of that molecule (13). In mammals, there 
are 5 major classes of heavy chains, denoted gamma (γ), alpha (α), delta (δ), mu (μ) and 
epsilon (ε) (1, 13). Immunoglobulins containing γ chains are termed immunoglobulin G 
(IgG) while those with α chains are immunoglobulin A (IgA), μ chains are 
immunoglobulin M (IgM), δ chains are immunoglobulin D (IgD) and ε chains are 
immunoglobulin E (IgE) (4). Each class (or isotype) of Ig may also consist of several 
subtypes depending on the species (4, 17). For example, equids have 7 subclasses of IgG 
while cattle have three IgG subclasses and pigs have six (12, 17, 18). Early research in 
equine immunology categorized the IgG subclasses according to their antigenic 
differences and four subclasses were defined: IgGa, IgGb, IgGc and IgG(T) (18). Since 
then, most of the subclasses have been linked to their corresponding Ig heavy chain 
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constant genes. As a result, there are more IgG subclasses than originally presumed, 
with some authors now designating them IgG1 – IgG7. What was once IgGa is now IgG1 
and IgG2, IgGb is now IgG4, IgGc is now IgG6 and IgG7 and IgG(T) is now IgG3 and IgG5 
(18).   
The main function of Ig molecules is to defend the body against a variety of 
invading microbes (16). As mentioned, several classes of Ig exist, each optimized to have 
different biological functions and act in various environments of the body such as blood, 
milk or mucosal surfaces (1). Immunoglobulin molecules range in size from 180-900 kDa 
(4). Immunoglobulin G, IgM and IgD are primarily synthesized in the spleen and lymph 
nodes, whereas IgE and IgA are largely synthesized in the intestinal and respiratory 
tracts (1, 19). Immunoglobulin G is the Ig found in highest concentration in the blood 
and is primarily responsible for defense against systemic pathogens. It has the smallest 
molecular weight of the 5 main Igs therefore allowing it to easily escape from blood 
vessels during periods of inflammation to participate in the defense against 
microorganisms in tissues and body fluids (1, 19). In most mammals, IgM has the second 
highest serum concentration and is the main Ig produced during a primary immune 
response, although it is also produced to a smaller extent in secondary immune 
responses (1). Immunoglobulin A is typically the Ig with the third highest concentration 
in the serum of most mammalian species. It is the predominant Ig in mucosal tissues 
and secretions and is therefore responsible for defence of the intestinal, urogenital and 
respiratory tracts and mammary gland (1, 4, 19). IgA is produced by plasma cells in the 
lamina propria underlying the mucosal epithelium and exists in one of two forms: 
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secretory IgA and serum IgA (19, 20). Receptors allow IgA to pass through epithelial cells 
into external secretions, such as saliva, intestinal fluids and milk, making it the primary 
Ig found in body secretions (19). Immunoglobulin E is found in very small concentrations 
in the serum and is responsible for mediating allergic reactions in the body and defense 
against parasitic infections. Finally, IgD is found on the surface of mature, naive B cells, 
however, its function is unknown at this time (1).  
1.1.3.2.4. Species-specific differences 
Although camelid species are economically important in many South American, 
North African and middle East countries, it was not until the mid-1990’s that 
investigations into their immune system began (21, 22). Prior to this time, it was 
believed that the antibodies of all mammalian species were similar in terms of general 
structure, and that all antibodies in domestic mammals consisted of two identical heavy 
chains bound to two identical light chains (23). However in 1993, Hamers-Casterman et 
al. challenged this common theory with their discovery of a novel class of IgG antibodies 
in the serum of camelidae (24, 25). These functional antibodies were termed heavy 
chain antibodies (HCAbs) as they were found to be completely devoid of light chains 
(26). Since this discovery, it has been ascertained that in addition to conventional 
antibodies, the serum of not just camelids, but also nurse sharks, wobbegong sharks, 
and possibly ratfish all contain antibodies lacking L-chains (27, 28). Currently, three 
subclasses of camelid IgG have been recognized: IgG1 which exhibits the conventional 
antibody structure, and IgG2 and IgG3 which do not contain associated light chains (29, 
30).  
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Several advantages for HCAbs have been identified when compared to their 
conventional antibody counterparts (25). For example, HCAbs seem to have a higher 
physicochemical stability and are therefore able to remain functional at higher 
temperatures than regular antibodies (25, 30). Also, due to the smaller size of HCAbs, 
they appear to have better biodistribution and tissue penetration in the body and are 
able to recognize antigenic sites which may not normally be recognized by conventional 
antibodies (25, 30).  
The discovery of functional antibodies devoid of light chains has drastically 
altered what was perceived to be the normal rules governing antibody structure (29). As 
investigation of the camelid immune system is still quite recent, a finding such as this 
brings up many potential questions and areas for further exploration. As a result, 
research into HCAbs is ongoing to establish the full potential and utility of such a 
molecule in human and veterinary medicine, as well as to clarify the roles they play in 
the camelid immune system (21, 26). 
1.2. Immunodeficiency disorders 
1.2.1. Overview 
In large animal veterinary medicine, immunodeficiency disorders often garner 
attention due to their potentially life-threatening consequences (1, 4). They occur when 
an animal’s immune system is compromised and not able to mount an appropriate 
immune response to ward off infectious disease (10).  Frequently these disorders are 
classified as either primary or secondary immunodeficiencies. Occasionally though, they 
may also be characterized by the specific immune system component affected (such as 
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humoral immunodeficiencies of which selective IgM deficiency would be an example) 
(10, 32, 33).  
Primary immunodeficiencies typically result from a defect in the animal’s 
immune system and usually have an alleged or established genetic basis (10, 32). They 
occur infrequently and may be difficult to diagnose (10). The most common primary 
immunodeficiencies encountered in large animal veterinary medicine include severe 
combined immunodeficiency disorder (SCID), selective immunoglobulin M (IgM) 
deficiency and foal (Fell pony) immunodeficiency syndrome (FIS) (10, 32, 34). Secondary 
immunodeficiencies are acquired and may result from failure of transfer of passive 
immunity (FTPI), malnutrition, neoplasia or immunosuppression by certain 
microorganisms or drugs (32). Other than FTPI, acquired immunodeficiences are 
uncommon in large animal veterinary medicine (35).  
1.2.2. Failure of transfer of passive immunity  
 
Newborn animals have different levels of immunologic competence at birth 
depending on the type of placentation found in their species, yet they all require 
assistance through the passive transfer of maternal Ig via the placenta or colostrum 
after birth (36, 37). Primates have the most intimate type of placentation, known as 
haemochorial, which allows for the in-utero transfer of IgG (36, 38). Dogs and cats have 
an endotheliochorial placenta where approximately 5-10% of IgG may be transferred to 
the neonate in-utero, with the remainder provided via colostrum (36). Alternately, 
ruminants have a syndesmochorial placenta and horses, pigs and camelids have an 
eplitheliochorial placenta (38, 39). Neither of these latter two forms of placentation 
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allow for in-utero transfer of IgG, resulting in neonates of these species essentially being 
born agammaglobulinemic (36-38).  
Following birth, foals and crias rely solely on the passive transfer of maternal 
antibodies, primarily IgG, from the dam’s colostrum (40, 41). Colostrum is a specialized 
form of milk produced in limited quantity in late gestation.  It contains a variety of both 
cellular and soluble components, with IgG being the most significant and predominant 
(35, 42, 43). For approximately 24 hours following birth, a neonate’s intestines are 
permeable to these colostral proteins which are not digested because the proteolytic 
activity of their gastrointestinal tract is minimal, and trypsin inhibitors present in 
colostrum further diminish enzymatic action (36). This decreased proteolytic activity 
allows colostral proteins to reach the small intestine, particularly the ileum, where they 
are taken up by epithelial cells and passed into the intestinal capillaries before finally 
reaching the systemic circulation (35, 36). Intestinal permeability is high immediately 
following birth but rapidly declines and by 24 hours of age, epithelial cells mature and 
become impermeable, and normal intestinal flora is established (36, 44).  
Through passive transfer, neonates are normally able to acquire large amounts 
of maternal IgG to provide a protective immune response in the first few weeks of life 
(36, 40). When a foal or cria is unable to do this, the resulting outcome is FTPI (10). There 
are several potential causes of FTPI which may result from problems with the dam, the 
offspring, or both. Factors attributed to the mother include inadequate production of 
colostrum or colostral IgG, premature lactation, or rejection of offspring thus not 
allowing them to suckle in the immediate post-partum period (10, 35, 41, 45). 
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Alternately, poor intestinal absorption (due to intestinal immaturity or ileus) or failure 
to ingest a sufficient amount of colostrum in the post-partum period due to injury, 
weakness, illness or injury in the neonate will lead to FTPI in foals or crias (10, 41, 44-
46).  
Failure of passive transfer of IgG has been associated with increased morbidity 
and mortality in foals, calves, lambs and crias (47-50). It is considered the most 
important risk factor for the development of infections, such as septicaemia, arthritis, 
enteritis, pneumonia and omphalitis in the first month of life (10, 30). Septicaemia is of 
particular concern as it is recognized worldwide as a major cause of foal and cria 
morbidity and mortality and been shown to be positively correlated with FTPI (32, 35, 
41, 51). The prevalence of FTPI has been reported as 20.5% in crias, up to 35% in calves 
and between 3 and 25% in foals (44, 48, 49, 52).  
Due to the potentially devastating consequences of FTPI, early and accurate 
diagnosis is required to provide effective medical intervention. Accordingly, multiple 
testing methods for FTPI have been developed and these are discussed more in-depth 
later in this chapter, however, the most quantitatively accurate test currently available 
is the single radial immunodiffusion (RID) assay (32, 49). Typically, serum IgG 
concentrations are measured at 18-24 hours following birth to allow adequate time for 
maximum IgG absorption (35). In foals, adequate passive transfer is achieved when 
serum IgG concentrations are >800 mg/dL (10, 32). Foals with IgG concentrations <400 
mg/dL are classified as having FTPI and foals with concentrations between 400-800 
mg/dL are categorized as having partial FTPI (49). In camelids, adequate transfer of 
17 
 
passive immunity is considered to have been achieved when serum IgG concentrations 
are >1000 mg/dl (30, 48).  
In cases where FTPI seems a likely outcome, preventative measures are the best 
option to minimize severity of disease. This may include providing an alternate high 
quality colostrum source, intravenous plasma transfusions, antimicrobial therapy and 
supportive care in a clean, low-pathogen risk environment (10, 30, 35). Ultimately, when 
treating patients with FTPI, clinicians must analyze each situation separately, including a 
thorough history, neonatal sepsis score, physical examination, complete blood count 
and immunoglobulin status, in order to make an appropriate treatment plan for that 
individual animal (10, 35).  
1.2.3.  Severe combined immunodeficiency disorder  
 
Severe combined immunodeficiency disorder is a fatal, inherited condition of 
humans, horses, dogs and mice (10, 42). It was first described in children in the 1960’s 
but it was not until 1973 that its first spontaneous animal counterpart was reported in 
Arabian foals (53, 54). In horses, SCID is an autosomal recessive trait thought to be 
restricted to Arabian or Arabian-cross breeds. However, single cases have also been 
reported in a Caspian filly and a Fell pony filly (33, 53). Affected foals have been 
identified throughout North America, Australia and the United Kingdom (55). Among 
Arabian horses in the United States, the frequency of SCID gene carriers has been 
reported to be 8.4% (32, 55, 56).  
Severe combined immunodeficiency disorder results from a 5-basepair deletion 
in the gene, located on chromosome 9, which encodes the catalytic subunit of the 
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enzyme deoxyribonucleic acid-protein kinase (DNA-PK) (10, 32, 55, 56). This enzyme is 
essential to gene rearrangement as it is required in the process of encoding specific 
antigen-receptor complexes on the surface of B and T lymphocytes (10, 53). Without a 
functional catalytic subunit, DNA-PK is rendered inactive and lymphocyte precursors are 
eliminated (53). Consequently, affected foals are born without functional T and B 
lymphocytes and therefore lack both cellular and antibody-mediated immunity (10, 32, 
53).  
Severe combined immunodeficiency disorder-affected foals appear normal at 
birth and may not show clinical signs until weeks or sometimes months later depending 
on the quantity of passive maternal antibody transferred and the extent of 
environmental microbial challenges encountered (10, 42, 53). As maternal immunity 
wanes, affected foals are unable to mount their own immune responses and become 
susceptible to a wide range of infections (10, 54). The respiratory tract is often the first 
system affected followed by gastrointestinal tract. The most common infectious agents 
identified in SCID foals include adenovirus, Rhodococcus equi, Pneumocystis carinii and 
Cryptosporidium spp. (10, 32, 53, 55). Initially, SCID-affected foals may respond to 
antimicrobial therapy, however infections continue to recur and most SCID-affected 
foals die in the first few months of life (10).  
Definitive diagnosis of SCID is achieved through genetic testing to demonstrate 
the presence of the mutant SCID gene (10, 53, 55). Prior to the advent of genetic testing, 
diagnosis of SCID was based on the clinical presentation of an Arabian foal with 
recurrent infections, a severe and persistent lymphopenia (<1000 lymphocytes/µl), an 
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absence of IgM in serum collected presuckle or after 3-4 weeks of age and presence of 
lymphoid hypoplasia at necropsy (10, 32, 53, 55). As medical management of foals 
diagnosed with SCID is unrewarding, euthanasia is warranted (32, 55). Due to the 
devastating consequences of SCID, prevention of this disease through responsible 
breeding practices and genetic testing is critical in Arabian horse breeding programs 
(32).  
1.2.4.  Selective immunoglobulin M deficiency 
 
Selective IgM deficiency is an uncommon disorder reported to occur in humans, 
foals and adult horses, and the pathogenesis of this condition is currently unknown (32, 
57). A genetic basis for selective IgM deficiency has not been proven and the association 
of this disorder with neoplasia and spontaneous recovery in some patients suggests that 
it may represent a secondary rather than primary immunodeficiency disorder in certain 
cases (32). This disorder was first reported in 1977 in a group of 5 horses between the 
ages of 2 months to 5 years old (10, 42). While it has been known to occur in a number 
of breeds, Arabians and Quarter Horses appear to be over represented in case reports 
(10, 42).  
In healthy horses, IgM accounts for approximately 10% of the total amount of 
circulating serum Ig (14, 15). Reference ranges of 120 (standard deviation ± 30) mg/dl 
have been reported for IgM concentrations in the adult horse (10, 32, 58). Originally it 
was proposed that to meet the criteria for a diagnosis of IgM deficiency, suspect cases 
must have serum IgM concentrations >2 standard deviations less than age-matched 
horses while all other Ig classes remained within normal reference ranges (32). Based on 
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current reference ranges, this would equate to serum IgM concentrations <60 mg/dl 
being deemed deficient (10, 58). However, another report has suggested adjusting the 
cutoff for IgM deficiency to <23 mg/dl as a number of “normal” horses analysed in the 
study had IgM concentrations falling below the 60 mg/dl value (10, 58). In foals between 
4 and 8 months of age, it is suggested that an IgM values <15 mg/dl, combined with 
normal values for all remaining Ig classes, is indicative of selective IgM deficiency (10). 
Due to the grave prognosis for this disorder, repeat IgM testing is warranted to confirm 
the diagnosis (42). 
Two clinical presentations of selective IgM deficiency have been recognized with 
the most common being a primary immunodeficiency observed in foals between 2 and 8 
months of age (42). Affected foals are typically small for their age and experience 
recurrent bacterial infections, often involving the respiratory tract (10, 32). Initially, they 
may respond well to aggressive antimicrobial therapy, only to relapse within a few 
weeks following the cessation of treatment (10, 42). The prognosis for selective IgM 
deficiency in foals is grave with the majority dying by 8 months of age (32, 59). Foals 
surviving beyond 1 year of age often fail to thrive and experience recurrent respiratory 
tract infections (10, 32, 42, 59). The second clinical presentation of selective IgM 
deficiency occurs in adult horses > 2 years of age (10). Originally a strong association 
was reported between IgM deficiency and lymphoma in adult horses (14, 15). More 
recently it has been recognized that this disorder may also be identified in horses 
diagnosed with a variety of conditions other than lymphoma (10, 32, 58). Therefore, a 
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true diagnosis of IgM deficiency requires the documentation of persistently low IgM 
concentrations (42). 
As there is no specific treatment for IgM deficiency, management of affected 
horses can prove difficult (10, 42). Due to the short half-life of IgM, plasma transfusions 
are not typically regarded as beneficial, and while supportive care and antimicrobial 
therapy may help manage bacterial infections initially, infections often recur following 
the cessation of treatment (32).  
1.2.5. Foal immunodeficiency syndrome 
 
A fatal, inherited disease of severe anemia, immunodeficiency and peripheral 
ganglionopathy has been recognized in the Fell and Dale pony breeds native to the 
British Isles (34, 42, 60). This condition, previously known as Fell Pony syndrome, is now 
termed foal immunodeficiency syndrome (FIS). It was first reported in a Fell pony foal in 
the United Kingdome in 1998, and currently affects approximately 10% of Fell and 1% of 
Dale foals (34, 61, 62). Research suggests FIS has autosomal recessive inheritance, and a 
recent study identified a mutation associated with the syndrome on the sodium/myo-
inositol cotransporter gene located on chromosome ECA26 (61, 62).  
Affected foals appear normal at birth with clinical signs including diarrhea, 
cough, failure to thrive, nasal discharge, depression and hypersalivation becoming 
apparent by 1 month of age (32, 60, 62). These animals may initially respond to 
treatment but recurrent infections occur as the result of a primary B-cell deficiency with 
an associated decreased antibody production (60, 61). T-lymphocyte concentrations 
remain normal in affected foals (61). Once maternal Ig levels decline by 3-6 weeks of 
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age, foals become immunodeficient as they are unable to generate an adaptive immune 
response due to impaired antibody synthesis (61). At the same time, these foals develop 
a severe, non-hemolytic, non-regenerative anemia and often die or are euthanized by 3 
months of age (60, 61).  
1.2.6. Juvenile llama immunodeficiency syndrome  
An immunodeficiency disorder characterized by ill thrift and recurrent, 
opportunistic infections has been described in juvenile llamas (63, 64). Termed juvenile 
llama immunodeficiency syndrome (JLIDS), affected animals often appear normal prior 
to weaning; with clinical signs typically developing between 2 to 30 months of age (63, 
65). Llamas with JLIDS present for weight loss, failure to thrive and recurrent infections, 
with clinical signs depending on the stage of JLIDS and the site(s) of infection (65).  
A complete blood count from JLIDS-affected llamas will reveal inflammation and 
a normocytic, normochromic, non-regenerative anemia. Measurement of serum IgG will 
reveal decreased concentrations (64, 66). Eperythrozoon organisms are commonly 
found in the peripheral blood smears and are considered secondary pathogens, typically 
only causing disease in immunocompromised hosts (66, 67). Llamas with JLIDS fail to 
respond to Clostridium perfringens C and D toxoid based on pre and post vaccination 
antibody titres, indicating a dysfunction in their acquired humoral immune response 
(64, 65). These animals will either fail to respond or respond poorly to conventional 
treatment of their infections and inevitably die or are euthanized due to a grave 
prognosis (63, 65). Necropsy findings often reveal hypoplasia or atrophy of lymphatic 
tissue (68). 
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The etiology of JLIDS is unknown but a number of genetic, infectious and 
environmental causes have been considered. A study by Davis et al. in 2000 found a 
defect in the development of B-cells in these animals and provided evidence of a genetic 
basis for JLIDS (63). It is unclear whether this disorder also affects alpacas. One case 
report in 1999 described an alpaca with clinical signs of JLIDS but no definitive diagnostic 
tests were performed prior to the death of the animal (63). JLIDS is diagnosed based on 
the aforementioned clinical signs, the results of a complete blood count and through 
ruling out other causes of ill-thrift and weight loss such as endoparasitism, malnutrition, 
dental problems, iron deficiency and congenital defects (65, 68).  
1.2.7. Other immunologic disorders 
Common variable immunodeficiency (CVID) is a rare disorder occurring in horses 
and humans (69). In horses, this disease has an unknown etiology. Cases in adults of 
both sexes, different breeds and geographical locations have been described (69-71). 
This disease is characterized by recurrent fevers and bacterial infections, particularly 
pneumonia, B cell lymphopenia or depletion and impaired humoral responses to protein 
vaccination (69-72). Hypo or agammaglobulinemia, most commonly involving IgG and 
IgM, is another frequent feature of this disorder (69). Cases of CVID have been reported 
in three adult horses with presumptive bacterial meningitis. This condition should be 
considered in adult horses with recurrent bacterial infections, meningitis, or both (69, 
71). Confirmation of CVID is through immunological testing. The prognosis has been 
described as guarded to grave depending upon concurrent clinical symptoms (69, 71). 
Some horses have been treated with continuous or intermittent antimicrobial and 
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immunoglobulin therapies, however, these options are economically impractical and 
raise concerns regarding antibiotic resistance and opportunistic infections (69).  More 
often, euthanasia is elected by owners due to the severity of infections such as 
pneumonia, meninigitis or septicaemia, the requirement for intensive clinical 
monitoring, treatment and hospitalization and the associated financial costs to do so 
(70, 71).  
A condition characterized as agammaglobulinemia has been reported in 5 male 
horses between 2 and 6 months of age (10). In humans, this condition occurs due to an 
x-linked inherited trait caused by a mutation in the Bruton tyrosine kinase gene (32).  As 
a result, only males are affected while female carriers appear clinically healthy (32). This 
disorder has currently only been reported in male horses, which is suggestive (but not 
indicative) of an x-linked mode of inheritance (10, 32, 59). Foals affected with 
agammaglobulinaemia present with signs of infectious disease, most often involving the 
respiratory, gastrointestinal or musculoskeletal systems (10, 73). These infections may 
initially respond to antimicrobial therapy but recurrence is common and most foals do 
not survive beyond 2 years of age (10, 32). Immunologic evaluation of foals with this 
condition reveals an absence of B lymphocytes with low or undetectable concentrations 
of immunoglobulins in the presence of normal T lymphocyte function (10, 32, 59, 73). 
Consequently, affected horses are unable to produce an appreciable antibody response 
following immunization (73). Treatment for this disorder is unrewarding and, until the 
specific genetic defect is identified, preventation is not possible (10).  
1.3. Diagnostic testing methods to determine immunoglobulin status 
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1.3.1.  Introduction 
Assessing different aspects of the humoral immune system in equine and 
camelid species is achieved by measuring serum or plasma Ig concentrations (74).  
Testing is extremely important as it allows for early and accurate diagnosis of 
immunodeficiencies and provision of timely medical intervention if indicated (49). The 
consequences of immunodeficiency disorders are emotionally and financially taxing for 
owners, thus there is a demand for up-to-date, economic, rapid and precise diagnostic 
options. As a result, multiple methods for the evaluation of Ig concentrations have been 
developed for animals resulting in a wide range of testing options, each with advantages 
and disadvantages (49).  
1.3.2. Testing methods currently available for immunoglobulin measurement 
in equine species 
Equine radial immunodiffusion (RID) assays are commercially available from a 
variety of manufacturers. They work on the principle that sample antigen (such as 
serum IgG) added to a RID plate well diffuses into the surrounding agarose gel which 
contains antiserum specific for the protein to be measured. A ring of antigen/antibody 
precipitate will form, which is proportional in size to the concentration of antigen in the 
sample. Reference sera zone diameters are measured and used to form a standard 
curve which is then used to determine the concentration of the protein of interest in the 
unknown sample (based on its measured ring diameter) (44, 52).  
The RID assays are currently the gold standard for determining serum IgG 
concentrations in horses as they provide the most quantitatively accurate results (44, 
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46). Unfortunately these assays require an 18-24 hour incubation period (44, 46). This 
substantial delay in obtaining results is a major disadvantage as quick identification of 
immunological disorders in foals, especially FTPI, is essential for timely therapeutic 
intervention (32, 44). Other disadvantages include a requirement for enhanced technical 
skill by the user, potential variation in different RID assays when calibrated to different 
standards, increased cost when compared with other testing methods and utilization of 
specific reagents with a limited shelf-life (46, 49).  
A number of other tests to estimate Ig concentrations in equine serum, plasma 
or whole blood are available (32).  These include zinc sulphate turbidity, glutaraldehyde 
coagulation and enzyme and turbidimetric immunoassays (10, 49). In calves, total serum 
protein (TSP) measurement by refractometry is a quick, inexpensive and accurate 
screening test for FTPI (46, 75). However, research indicates this method is an unreliable 
predictor of FTPI in neonatal foals due to their wide range of TSP concentrations (46, 
75). A latex agglutination test is also available for the detection of FTPI in foals, 
however, it is considered an inappropriate screening method due to poor sensitivity and 
specificity (10). 
The glutaraldehyde coagulation test is a simple, inexpensive and rapid 
semiquantitative FTPI screening test which can be performed in a field setting with 
results in minutes (76). This test has a good sensitivity for the diagnosis of FTPI but 
suffers from poor specificity, especially for IgG concentrations <800 mg/dl (32, 46). As a 
result, the predictive value of a negative test is reliable but a positive test does not 
necessarily indicate FTPI in that animal and confirmatory testing is warranted (32). Two 
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studies comparing glutaraldehyde coagulation tests with RID assays in neonatal foals 
found sensitivities of 100% and 92.9% and specificities of 59% and 58.6% for the 
glutaraldehyde test when identifying IgG concentrations <800 mg/dl (46, 77).  
The zinc sulphate turbidity test is another FTPI field screening test that is 
relatively cheap and rapid, providing results in approximately 1 hour (10, 32). However, 
similar to the glutaraldehyde coagulation test, it also suffers from poor specificity, with 
one study reporting a sensitivity of 81% and specificity of 56.9% for the detection of 
serum IgG concentrations of <800 mg/dl in foals (46). In addition, both the 
glutaraldehyde coagulation and zinc sulfate turbidity tests are nonspecific for IgG as 
they are able to detect other serum proteins which may lead to false positive test 
results (49, 78). 
Turbidimetric immunoassay (TIA) can be used for the detection of IgG in equine 
serum (44). The assay provides accurate, rapid, quantitative data and can now be 
measured on a routine chemistry analyzer commonly found in many clinical veterinary 
laboratories (44, 79). Benefits of TIA over RID include complete automation and a 
greatly decreased turnaround time for results. In one study, TIA sensitivity and 
specificity were 91.5% and 70.5% for the detection of plasma IgG concentrations <800 
mg/dl in foals and 92.3% and 99.1% for IgG concentrations <400 mg/dl. This study 
concluded that the TIA-generated values were highly correlated with the RID-generated 
values (79). A disadvantage of TIA is the requirement for specific reagents with a limited 
shelf-life (44). 
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A number of quantitative and semiquantitative enzyme-linked immunosorbent 
(ELISA) assays are commercially available for the detection of Ig in equine serum, plasma 
or whole blood (10). A semiquantitative stall-side ELISA (Snap Foal Test, IDEXX, 
Westbrook, ME) is popular among practitioners for the diagnosis of FTPI in foals due to 
its ease of use and rapid results (10, 75, 80). One study found sensitivity and specificity 
values of 81% and 94.7% for the detection of serum IgG concentrations <800 mg/dl in 
foals when using the SNAP test (46). Another study, looking at hospitalized foals only, 
found the sensitivity of the SNAP test for detecting serum IgG concentrations <800 
mg/dl was 95% while the specificity was 52% (75). Disadvantages of ELISAs include the 
use of heat and contamination-sensitive reagents and generally a higher cost per test 
than other screening methods (49).  
More recently, Fourier-transform infrared (FTIR) spectroscopy has been 
investigated as a new testing method for IgG quantitation in equine serum (49). A study 
by Riley et al. in 2007 measured serum IgG concentrations in foals using FTIR analysis 
and compared these results to RID-derived concentrations. The sensitivity, specificity 
and accuracy for the FTIR-based test were 92.5%, 96.8% and 95.9% for the diagnosis of 
FTPI in foals. As a result, the authors felt that the overall performance of the IR-based 
was similar to the current gold standard RID assay and an accurate means for FTPI 
diagnosis in foals (49).  
Few testing options are available for the measurement of Ig isotypes other than 
IgG or for the different IgG subclasses. Past literature exploring equine immunology 
utilized RID assays (VMRD Laboratories Inc.) for Ig isotype quantitation, yet these are no 
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longer commercially available (81, 82). Currently to this authors’ knowledge, only ELISAs 
(Bethyl Laboratories Inc.; Montgomery, TX) are available for IgM, IgA and IgG(T) 
quantitation (ELISAs produced by the same company for IgGb and IgGa analysis have 
been discontinued by the company since 2012). 
1.3.3. Testing methods currently available for immunoglobulin measurement 
in camelid species 
Significant research has gone into assessing the commonly used tests available 
for the measurement of Ig in foals and calves. In contrast, few studies have looked at 
evaluating these same tests in the various camelid species (52). Methods that have been 
evaluated for diagnosing FPT in camelids include measurement of total serum protein, 
globulin and albumin, measurement of serum gamma glutamyltransferase (GGT), zinc 
sulphate turbidity, glutaraldehyde coagulation, sodium sulphate precipitation, TIA and 
RID (52, 74, 83). 
Radial immunodiffusion is a testing method available in camelids which provides 
quantitative IgG concentrations (52, 68, 83). Currently, only one RID assay is available 
for commercial use (Llama IgG Test Kit, Triple J Farms, Redmond, WA) as a second RID 
assay (Llama VET-RID, Bethyl Laboratories, Montgomery, TX) previously available has 
been discontinued by manufacturer’s (52, 68). One study demonstrated these two RIDs 
were not in agreement for the measurement of camelid IgG. The authors concluded it 
was not possible to determine which assay more accurately predicted the actual IgG 
concentration as no other gold standard method was available for measuring camelid 
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IgG (68). Regardless, the RID assay currently available suffers the same disadvantages as 
in the equine RID assays previously discussed (52).  
A few studies have looked at using different components of serum, such as total 
protein, albumin, globulin and GGT, as aids in the diagnosis of FTPI in crias (40, 83). In 
one study, results revealed no significant association between GGT activity and IgG 
concentrations determined via RID (40, 52). A second study corroborated this finding 
but did indicate that TSP and globulin concentrations were significantly associated with 
serum IgG concentrations and therefore are potential methods for identifying suspect 
cases of FTPI in crias (52). This study found that using a TSP endpoint of ≥5.0 g/L, the 
proportion of crias correctly diagnosed with FTPI was 72% with a sensitivity of 71% and 
specificity of 80% when compared with RID IgG values (52). For globulins, an endpoint of 
≥2.5 mg/dl led to the correct classification of 70% of crias with a sensitivity of 64% and 
specificity of 100% (52). Serum albumin is not considered predictive of FTPI in crias (52, 
83).  
One study looked at using both the zinc sulphate turbidity and the 
glutaraldehyde coagulation tests for estimating IgG values in crias (83). When compared 
to RID, the zinc sulphate turbidity test had a sensitivity of 100%, specificity of 54.3% and 
accuracy of 69.4%. The glutaraldehyde coagulation test had a sensitivity of 78.4%, 
specificity of 91.2% and accuracy of 83.5% when compared with the RID results (83). The 
authors cautioned against using the glutaraldehyde coagulation test for FTPI screening 
in crias due to its low sensitivity and concluded that the zinc sulphate turbidity test was 
not accurate for identifying low IgG concentrations in camelids (83). 
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A sodium sulphate turbidity test (Llama-S, VMRD, Pullman, WA) is commercially 
available for the estimation of IgG concentrations in camelid serum (52). This test 
provides rapid, semiquantitative results and is user-friendly and inexpensive. One study 
found that using an endpoint of 300 mg/dl in the commercial sodium sulphate turbidity 
test generated a sensitivity of 89%, specificity of 100% and accuracy of 89% when 
compared with the results produced by RID (52).  The authors concluded it was an 
appropriate method for assessing FPT in crias if used at an endpoint of 300 mg/dl rather 
than the 600 mg/dl or 1200 mg/dl recommended manufacturer’s endpoints (52). 
A recent study investigated the diagnostic agreement for IgG measurement in 
alpaca serum between the currently available RID assay and 2 new commercially 
available TIA assays (84). The authors found a lack of agreement between the 3 methods 
with the significant differences between assay results mainly attributed to their use of 
different standards (84). Of the 3 assays, RID was found to be the most imprecise 
leading the authors to question if the RID assay should continue as the “gold standard” 
for camelid serum IgG quantification or whether a more automated and precise 
method, such as TIA, should be adopted (84). 
Ultimately, it is important to take all factors, including accuracy, time 
requirements, ease of use and cost, into account when selecting a test for the 
measurement of Ig concentrations. When results are questionable, or in those tests with 
low specificities, confirmation of results with another testing method is recommended 
(10).  
1.4. Fourier Transform Infrared Spectroscopy of Biological Samples 
32 
 
1.4.1. Overview 
 
Discovery of the infrared (IR) region of the electromagnetic spectrum by Sir 
William Herschel in 1800 was the pioneering step leading to the development of IR 
spectroscopy (85, 86). Within 35 years of this discovery, the first mid-infrared 
spectrometer was constructed and in 1913 the first commercially available IR 
spectrometer was manufactured (85, 87). However, it was not until approximately 30 
years later, during World War II, that the usefulness of IR spectroscopy was realized in 
both industry and medical research (87). It was during this period that the breakthrough 
of IR spectroscopy occurred when it was employed for various projects such as the 
analysis of petroleum and identifying the structure of penicillin (87). Following World 
War II, an increase in industrial manufacturers led to a surge in the number of IR 
spectrometers in the United States, most with better design and flexibility than prior 
models. This in turn led to a quick growth in the use of IR spectroscopy for analysis of 
various chemical and biological systems (87).  
A significant advancement in IR spectroscopy came with the production of 
Fourier-transform infrared (FTIR) spectrometers (87).  These machines were able to 
drastically improve the quality of data obtained by using an interferometer in 
combination with the mathematical process of Fourier transformation (88). In 1969, 
Digilab produced the first commercially available computer-controlled FTIR that quickly 
led to an increase in the use of this technology to study different types of biomolecules 
(87). In the past few decades, enormous advances in instrumentation and 
computational power have allowed for the growth, refinement and widespread 
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implementation of FTIR in industry and biomedical research (86, 87). Today, FTIR 
spectrometers are able to routinely produce large volumes of data that would have 
been inconceivable only a mere decade ago (86). This ability allows for the analysis of 
complex biological samples, yet has created the need for the development of 
sophisticated methods of data interpretation. As a result, biomedical spectroscopists 
now use chemometrics and other mathematical processing methods to gather 
significant amounts of information from the generated spectra (86).  
1.4.2. Principles of operation and use 
The electromagnetic spectrum is made up of several regions of radiation 
including radiowave, microwave, infrared, visible, ultraviolet, x-rays and γ-rays (88). The 
IR portion of the electromagnetic spectrum lies between the microwave and visible 
sections and is divided into three regions, near-IR, mid-IR and far-IR, based on their 
relation to the visible region of the spectrum (89). The positions of IR absorption on the 
spectrum are typically presented as wavenumbers (cm-1) or wavelengths (µm) with 
wavenumber defined as the number of waves per unit length (i.e. cm). The relationship 
between wavenumber and wavelength (λ) can be represented as wavenumber = 
1/wavelength (88, 89). Information produced from the measurement of IR absorption is 
often presented as a spectrum with wavenumber (or wavelength) on the x-axis and 
absorption intensity on the y-axis (89).  
As mentioned previously, the IR spectrum is divided into three subsections: the 
near-IR (14285-4000 cm-1), mid-IR (4000-400 cm-1) and far-IR (<400 cm-1) (88). In 
particular, the mid- and near-IR regions have gained specific interest in analytical 
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chemistry for their ability to diagnose or solve various clinical problems in human and 
veterinary medicine (88, 90). Factors which help the researcher decide as to the 
suitability of mid or near spectroscopic techniques include the disease process and type 
of tissue to be analysed, sample thickness and volume, and whether in-vivo or ex vivo 
measurements are desired (91, 92). 
The basis for infrared spectroscopy is that all molecules within a sample are in 
continuous vibration at temperatures above absolute zero (89, 93). When IR light is 
transmitted through a sample in a FTIR spectrometer, molecules within that sample will 
absorb light when a specific vibrational frequency is matched by the frequency of the IR 
radiation (93). The amount of radiation absorbed at a specific wavenumber is measured 
by an IR spectrometer and displayed as absorption bands on an IR spectrum. The IR 
spectrum of a multi-component sample (such as the biological samples of interest here) 
will consist of numerous absorption bands at different wavenumbers; each unique 
chemical component contributes its own unique vibrational spectrum (absorption 
pattern), and the measurement thus yields a superposition of the spectra for the various 
different biomolecules in that sample (93, 94). Small molecules will generate simple 
spectra with their chemical structure reflected by well-defined absorption bands. In 
contrast, complex samples are composed of an increased number of biomolecules thus 
generating spectra with an increased number of absorbance bands, many of which will 
overlap (94). It is important to note that the IR spectrum of a sample depicts both the 
structure and abundance of the IR active components within that sample. Therefore, 
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changes to either of these features will result in changes in the absorbance bands of the 
sample’s spectrum (49, 93). 
The oldest, most basic form of IR spectroscopy is transmission spectroscopy 
whereby the absorption of IR radiation is measured as a function of wavelength when it 
is passed through a sample (88). Any state of sample can be analyzed using transmission 
spectroscopy. With aqueous samples, the strong absorptions bands produced by water 
within the sample may overlap with the absorption bands of interest on the spectra, 
thereby making it difficult to obtain meaningful results (85, 88). Two options to 
overcome this obstacle have been identified. These include allowing the liquid to dry 
(and thereby removing the water) and form a film which can then be analyzed, or using 
more advanced techniques such as attenuated total reflectance (85). 
Following the acquisition of an IR spectrum for a given sample, the challenge is 
to then extract information which will provide clinically useful data (88). As modern 
spectroscopic equipment can now provide large volumes of data in a short period of 
time, it has created the need to develop sophisticated interpretative methods for data 
analysis.  As mentioned earlier, the use of chemometrics and other mathematical 
processing techniques has aided in this process, providing new solutions for data 
acquisition that were previously not available (86). These chemometric techniques 
provide the basis to develop either quantitative analytical methods or classification 
methods (e.g. “healthy” vs. “diseased”) that provide the basis for categorical diagnostic 
tests (86, 95, 96). 
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To optimise the accuracy of the analytical method, the spectra are often 
preprocessed with the aim of amplifying useful information latent within them, and 
suppressing irrelevant features and noise. Some of the techniques commonly employed 
for this purpose, and utilized in this research project, include spectral smoothing of data, 
standard normal variate transformation of spectra and partial least squares regression 
(97-99). The premise behind smoothing of the spectral data is that the information 
output from an experiment will contain both the measurements of interest as well as 
random errors superimposed upon and indistinguishable from these measurements 
(these errors are commonly referred to as noise) (99).  As a result, the Savitzky-Golay 
method was developed with the intent of removing as much of this noise as possible 
while maintaining the integrity of the underlying measurements (99).  
Processing of IR spectra via standard normal variate transformation is often 
performed with the intent to remove the interference of radiation scatter within an 
individual spectrum (97). Subsequently, it is useful to reduce within-set-sample variation 
among the spectra and generate a more uniform, manageable set of data (97).  
Once the spectral preprocessing is complete, partial least squares (PLS) 
regression is utilized as the basis to develop a quantitative analytical method. To begin, 
the method explores the relationship between IR spectra generated for each sample of 
interest and their corresponding “true” reference standard concentration values (i.e. 
RID or ELISA-derived Ig concentrations in this project) (100). This process yields a 
“calibration model” that is capable of converting spectroscopic data into useful 
quantitative analytical data (49). The accuracy of this provisional analytical method (the 
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PLS algorithm that takes a spectrum as input and provides concentration value as 
output) is then verified by using it as the basis to predict concentrations for “unknown” 
validation, or test samples. This provides an estimate of the predictive accuracy of the 
method in clinical use (49).  
1.4.3. Advantages of Fourier-transform infrared spectroscopy 
There are numerous advantages to the use of FTIR spectroscopy for the 
quantitative and qualitative characterization of biological samples. Perhaps one of the 
most distinguishing features is that no reagents are required as the spectra generated 
are the direct result of IR-active components within the sample of interest (90). Due to 
this, there is no requirement for chemical modification of the sample or comparative 
substances or standards (49, 90, 91). An additional advantage of this approach is that it 
is an economical testing modality with a low per-sample cost and inexpensive repeat 
testing (49). Another benefit with FTIR spectroscopy is that results can be available 
within minutes. This advantage, combined with no reagent requirements, make IR 
based testing methods well suited for point-of-care use in diagnostic laboratories, 
operating theatres, emergency rooms or veterinary clinics (49, 101).  
An important feature of FTIR spectroscopy is that almost any form of a sample, 
including gas, solid or liquid, can be successfully analyzed, often with only a small 
sample volume required. For instance, mid-IR spectroscopic analysis can be performed 
on using ≤10 µl of sample volume while near-IR typically requires only 0.1-0.2 ml of 
sample (89, 91). Modern FTIR-based analytical methods are also amenable to 
automation (91).    
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An attractive feature of FTIR spectroscopy is its ability to identify spectral 
“signatures” or “fingerprints” of disease due to its sensitivity in identifying changes at a 
molecular level in cells and tissues (49, 102). In theory, the IR spectrum obtained from a 
fluid or tissue will depict the absorptions from all major biomolecules present within 
that sample, with the relative absorbance intensity of each correlating to its relative 
concentration (103). Therefore, the IR spectrum from a specific type of tissue or fluid 
may be considered characteristic. Consequently, if a disease process changes the 
composition of a fluid or tissue, it will alter the molecular fingerprint of that sample 
which should be diagnostic (103). As a result, spectral differences have been found 
between normal and diseased tissues or fluids, aiding in the detection and classification 
of numerous diseases (90, 93, 104).  
As demonstrated below, many studies have proven FTIR-based analytical 
methods to have excellent accuracy and sensitivity in the screening, diagnosis and 
classification of disease (49, 94, 104-106). These results, combined with the numerous 
aforementioned advantages, make FTIR spectroscopy a promising technique in the 
future of human and veterinary health care. 
1.4.4. Practical applications of infrared spectroscopy in human medicine 
1.4.4.1. Overview 
Infrared spectroscopy has emerged as a powerful diagnostic tool in analytical 
chemistry for the quantitative and qualitative analysis of biological fluids in both human 
and veterinary medicine (85, 90). It has promise in the development of more practical, 
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accurate biomedical tests and current research demonstrates its potential in the study 
of pathological disease processes (85, 90).  
1.4.4.2. Infrared Clinical Chemistry 
Infrared clinical chemistry is the quantitative determination of analytes of 
interest in biological fluids through analysis with IR spectroscopy (85). Significant 
research has been undertaken in this field to investigate the use of IR spectroscopy in 
multiple areas including serum and urine component quantitation, assessment of fetal 
lung maturity, saliva component quantitation and the diagnosis and classification of 
arthritis through synovial fluid analysis (85, 103).  
A number of studies have demonstrated the potential for FTIR in a clinical 
chemistry laboratory setting (96, 101). Whole blood, plasma, serum and urine samples 
are all composed of a variety of different components, such as proteins, clotting factors, 
Igs, etc., each of which have their own unique IR absorption pattern (91, 96, 101, 107). 
This unique IR pattern provides the basis to distinguish among the different sample 
constituents and separately quantify them, thus providing a multitude of useful clinical 
data from a single sample (91). Multiple analytes of importance in both veterinary and 
human medicine have proven suitable for FTIR based analysis in prior studies. These 
include total protein, albumin, glucose, triglycerides, urea, creatinine, lactate, fibrinogen 
and cholesterol (91, 96, 101, 107). As a result, it may be possible for FTIR spectrometers 
to become a part of routine analytical methods in diagnostic chemistry laboratories in 
the future.  
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In humans, there are a number of diseases that can significantly affect joint 
mobility and potentially progress to disability and joint deformities. These include 
osteoarthritis, rheumatoid arthritis and spondyloarthropathy (95, 103). Diagnosis of 
these diseases is typically through a combination of clinical history and physical 
examination with other diagnostic methods (such as radiology, magnetic resonance 
imaging and laboratory tests) used to verify clinical suspicions. However, obtaining a 
diagnosis through such methods can often be labor intensive, costly and time 
consuming. Additionally, in some cases a diagnosis may not be reached for several 
months if clinical symptoms are not significant enough to be diagnostically definitive 
and by that time irreversible damage to the joint may have occurred (103). Recently, IR 
spectroscopy has been investigated for its use in the diagnosis of arthritis via synovial 
fluid analysis (95, 103).  
Two studies measured the IR spectra of synovial fluid and combined these with 
linear discriminant analysis to categorize the type of disease present in a given joint 
(either as osteoarthritis, rheumatoid arthritis or spondyloarthropathy) (95, 103). They 
hypothesized that the different disease processes would each alter the composition of 
synovial fluid in the associated joints and that this alteration would create a diagnostic 
molecular fingerprint on IR spectra (103). Results confirmed that the IR spectrum of 
synovial fluid from each of the three types of diseased joints differed significantly from 
each other, thus allowing for disease classification based on the different synovial fluid 
spectra (95, 103). This work indicates that IR spectroscopy may be useful as an aid in the 
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diagnosis of arthritic conditions through the analysis of synovial fluid from affected 
joints.  
1.4.4.3. Infrared Pathology 
The term infrared pathology refers to the analysis of excised tissues or isolated 
cells by IR spectroscopy to further investigate disease processes within the body (85). In 
the past few decades, this concept has gained notice in the field of oncology with 
numerous studies indicating the potential for FTIR spectroscopy in the screening, 
diagnosis or characterization of cancerous cells and tissues (92, 105, 108). Results of 
these studies indicate IR spectroscopy is able to reliably detect changes in the 
biochemical composition of cells at a molecular level and as a result, its use has been 
investigated in a variety of cancers including cervical, esophageal, breast, gastric, 
colorectal and certain leukemias (85, 93, 106, 109-111). 
Worldwide, cervical cancer is the second leading cause of cancer-related death 
in females, with more than half a million cases diagnosed yearly (112). The introduction 
of cervical cancer screening methods by Papanicalou in the 1960s and 1970s led to a 
decrease in the prevalence of cervical cancer by 75% between 1955 and 1992 yet 
despite this, incidence rates of cervical cancer are still high, particularly in under-
developed countries where screening programs are lacking (112, 113). Currently, 
cervical cancer screening is done via a pap smear where exfoliated cervical cells are 
collected and undergo cytologic examination, yet this method is widely recognized as 
having a low accuracy due to the occurrence of false negative results (113). As a result, 
alternate methods for cervical cancer screening are under investigation with numerous 
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publications found in recent literature assessing the use of IR spectroscopy for this 
purpose (104, 109, 113-116).  
Earlier research investigating the use of IR spectroscopy for cervical cancer 
screening focused on detecting changes at the molecular level in diseased cells (104, 
114). One study by Wong et al. was able to determine that the infrared spectra obtained 
from normal cervical cells were significantly different than the spectra obtained from 
abnormal cells (those with either cervical cancer or dysplasia) due to alterations in the 
intensity of various bands in different spectral regions. They concluded that the spectral 
changes found in dysplastic cells were the same as those in cancerous cells, just to a 
lesser magnitude (114).  
More recently, studies have focused on the application of IR spectroscopy in a 
clinical setting for the detection of cervical cancer in comparison with the current 
standard screening method (pap smear) (109, 116). One study compared FTIR 
spectroscopy screening of exfoliated cervical cells to pap smear cytology screening in 
301 samples using colposcopic biopsy as the gold standard for cervical cancer diagnosis 
(109). Results of this study generated a sensitivity and specificity of 98.6% and 98.8% for 
FTIR and 86.6% and 90.5% for pap smears. The false negative rates differed significantly 
between the two testing methods in favor of FTIR (1.4% for FTIR versus 13.4% for pap 
smears). Based on these promising results, further investigation into the role of IR 
spectroscopy in the screening of cervical cancer is warranted (109). 
Significant research efforts have been employed in the fields of gastric and colon 
cancer detection through use of IR spectroscopy (102, 106, 108, 110, 117, 118). Similar 
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to with other forms of cancer, IR spectroscopy has been used to successfully identify 
alterations in the spectrum generated from malignant gastric and colon tissues when 
compared to normal tissues (108, 118). In one study, 10 bands in the region of 925-1660 
cm-1 were identified as having significantly greater absorptions in the malignant gastric 
tissues than in normal tissues. By using these absorption bands and linear discriminant 
analysis, 22 out of 23 gastric cancer samples and 9 out of 12 normal gastric tissue 
samples were correctly categorized yielding an accuracy of 88.6% (with a sensitivity of 
96% and sensitivity of 75%) for the classification of gastric tissue samples in this study. 
The high sensitivity in this study, comparable to or better than certain other current 
methods of gastric cancer screening, depicts FTIR spectroscopy as a promising technique 
for the differentiation between normal and malignant gastric tissues (108). 
Breast cancer is one of the most commonly diagnosed and significant forms of 
cancer in woman worldwide, with a rapidly increasing incidence and a mortality of up to 
40% (119). As a result, rapid, accurate techniques for early screening of breast cancer 
are required.  Mammography is currently the most common screening tool for breast 
cancer, but has various limitations including a high degree of false positive results (due 
to its poor ability to identify cancerous lesions in radiologically dense breast tissue) 
(119). Therefore, considerable research efforts have focussed on determining whether 
IR spectroscopy may be a clinically useful tool in screening, characterization and staging 
of breast cancer (85, 119). 
Use of IR spectroscopy in the analysis of breast tissue can be more difficult than 
with other forms of tissue due to the complex matrix of adipose tissue and collagen 
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which anchors the epithelial cells of the breast (85). There exists a large variation in 
normal breast tissue composition, which in turn generates numerous variations in the 
spectral characteristics of breast tissue in almost all regions of the spectrum. Due to this 
variation, less pronounced changes in the spectrum, such as those relating to 
progression of the disease within the epithelial cells, may be more difficult to identify 
(85).  
Despite this inherent complexity of breast tissue, one study was able to illustrate 
that a large amount of clinically relevant information may still be obtained from the 
spectra of breast tissue samples using appropriate pattern recognition methods (85). In 
this study, a linear discriminant algorithm was used to identify spectral features that 
were considered characteristic of high, intermediate and low grade breast tumors. The 
accuracy of the algorithm to correctly classify high, intermediate and low grade breast 
tumors was 100%, 76.5% and 90.5% respectively (85). 
1.4.4.4. Other applications in human medicine 
The aforementioned fields of medicine are just a portion of those where the use 
of IR spectroscopy is currently being explored for its application in the screening, 
diagnosis or classification of disease. Other areas where researchers are delving into the 
use of IR spectroscopy for medical purposes include characterizing Alzheimer’s disease 
tissue and the non-invasive measurement of tissue perfusion and haemoglobin oxygen 
saturation (85). IR spectroscopy is also under investigation for its use as a non-invasive 
screening tool in various dermatological and arthritic disease processes as well as for its 
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application in the determination of fetal lung maturity through amniotic fluid analysis 
(92, 120-123).       
1.4.5. Practical applications of infrared spectroscopy in veterinary medicine 
1.4.5.1. Overview 
Following the success of IR spectroscopy in various aspects of human medicine, 
research has emerged exhibiting its promise in the field of veterinary medicine. As a 
logical next step, many of the concepts and techniques of IR spectroscopy that were 
developed for use in human medicine, have been utilized to screen, diagnose or solve 
similar clinical problems in animals (94, 124).  
1.4.5.2. Arthrology 
Musculoskeletal disorders are common in equine athletes and can have 
significant effects on the animal’s well-being and performance ability. Osteoarthritis is 
one such disease which involves the synovial joints and is characterized by cartilage 
degeneration, osteophyte formation, subchondral bone sclerosis and inflammation of 
synovial structures (125). The incidence of osteoarthritis-induced lameness in 
performance horses is quite high with one study implicating it in 54% of lameness cases 
admitted to one veterinary teaching hospital (125). Another important musculoskeletal 
disorder in horses is osteochondrosis. Osteochondrosis is considered a developmental 
orthopedic disease characterized by failure of endochondral ossification leading to 
articular cartilage damage and subchondral bone defects in affected joints. It has a 
reported prevalence in the literature ranging from 10% - 31.5% making it another 
significant cause of lameness and poor performance in equine athletes (90).  
46 
 
Numerous diagnostic modalities are available for the identification of 
osteoarthritis and osteochondrosis in horses. Recent studies performed at the Atlantic 
Veterinary College (AVC) investigated the potential for IR spectroscopy in this area (90, 
94). One study hypothesized that osteochondrosis in an equine joint may alter its 
synovial fluid composition thereby creating different IR absorption patterns in synovial 
fluid samples obtained from affected joints (90).   This study compared the IR spectra 
generated from synovial fluid samples of joints with osteochondrosis to those of normal 
joints and found significant features in the IR absorption pattern of samples taken from 
osteochondrosis-affected joints (90). The classification success rate for this study was 
promising at 77% but the authors noted that a larger sample size in future FTIR-based 
studies of osteochondrosis would be ideal to improve the accuracy and range of 
applicability to a larger, more diverse diseased population (90).   
A similar study looking at traumatic arthritis rather than osteochondrosis in 
horses was also performed at the AVC (94). The hypothesis was similar in that the 
authors believed traumatic arthritis in an equine joint would lead to changes in the 
synovial fluid composition of that joint which could be detected by alterations in the IR 
absorption patterns when compared to control samples. A classification model was 
developed, from a calibration dataset, with its performance determined by the use of 
two validation datasets. The model was able to classify spectra from the calibration 
dataset with an overall accuracy of 97%, sensitivity of 93% and specificity of 100% and 
yielded an overall accuracy of 89% and 100% for the validation datasets (94). These 
results show that alterations in the IR spectroscopic absorption patterns of synovial fluid 
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obtained from traumatic arthritis-affected joints may be used with an appropriate 
classification algorithm for the diagnosis of this equine joint disease (94).  
1.4.5.3. Transmissible spongiform encephalopathies 
Infrared spectroscopy has been studied for its feasibility in the screening and 
detection of infectious diseases such as transmissible spongiform encephalopathies 
(TSEs) (124, 126-129). This family of diseases, which includes scrapie in sheep, bovine 
spongiform encephalopathy (BSE) in cattle, chronic wasting disease in deer, 
transmissible mink encephalopathy in mink and Creutzfeldt-Jakob disease in humans, is 
a group of fatal neurodegenerative diseases resulting from changes to the prion 
proteins in brain tissue (124, 126). Due to the severe public health and economic 
concerns these diseases generate, research in the past few years has focused on the 
development of rapid, reliable diagnostic tests for TSEs (124).   
In recent years, IR spectroscopy has been used to analyse the blood and tissues 
from TSE-affected animals (124, 126-129). Kniepp et al. examined brain tissue harvested 
from both scrapie-infected and non-infected hamsters in attempts to identify preclinical 
and clinical pathological changes in the brain specimens from diseased hamsters (128, 
129). Through comparison of the IR spectra of the scrapie-infected and control brains, 
consistent alterations in both protein composition and carbohydrate and nucleic acid 
components were identified within the scrapie-infected brains. These results show IR 
spectroscopy is able to detect certain molecular changes which allow for spectral 
discrimination between normal hamster brain tissue and the brain tissue from hamsters 
with preclinical, clinical and terminal-stage scrapie (128, 129).  
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More recently, studies have looked at using IR spectroscopy for the antemortem 
diagnosis of BSE in cattle serum (124, 126, 130). Researchers found that the composition 
of serum samples from BSE-affected animals was slightly, but characteristically, altered 
thereby providing “signatures” specific to BSE on their associated IR spectra (124, 126). 
These results display a method for antemortem BSE diagnosis via serum, but further 
work is required to determine whether these same BSE-specific “signatures” can also be 
identified in animals prior to the onset of clinical signs of disease (126).  
1.4.5.4. Dairy herd health management 
Large scale dairy herd operations are common practice in North America and 
other parts of the world with producers continuously looking for ways to improve cow 
heath and increase their quality and quantity of milk production. Infrared spectroscopy, 
often in combination with chemometrics, has been investigated for these purposes with 
success in various aspects of heard health management (131-134).  
Primary ketosis in dairy cattle occurs in the postpartum period due to insufficient 
energy intake. This metabolic disorder is associated with lower milk yield, increased 
time to first ovulation and lower fertility in affected cattle (131, 132). Measurement of 
acetone concentration in milk is one method for ketosis diagnosis in dairy cattle with 
recent research looking into the use of IR spectroscopy for this purpose (131, 132). 
Typically, the concentration of acetone in milk ranges between 0-2 mM with 
concentrations <0.7 mM indicating the cow is healthy, 0.7-1.4 mM indicating potential 
subclinical ketosis and >1.4 indicating ketosis (132).  
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Two independent studies were both able to determine that acetone can be 
found at two locations in the mid-infrared spectral region: 1370 cm-1 and 1239 cm-1. 
Based on this information, one study reduced the spectrum of analysis for acetone 
(from 3000-1000 cm-1 to 1450-1200 cm-1) and combined FTIR spectroscopy with partial 
least squares regression to successfully identify subclinical ketosis in cattle (131). Using 
this method and a threshold of 0.4-1.0 mM for subclinical ketosis, the study was able to 
develop an accurate testing method for subclinical ketosis with a sensitivity of 95-100% 
and specificity of 96-100% (131).  
Other studies have investigated the reliability of IR spectroscopy as a diagnostic 
tool for the measurement of milk components such as somatic cell count and milk urea 
nitrogen (MUN) (133, 134). As machines are now commercially available which utilize 
FTIR spectroscopy for milk sample analysis, research is necessary to determine whether 
this new technology is able to consistently produces results comparable to or better 
than the historically accepted methods of analysis (133). One study, performed at the 
AVC, found no significant differences between an IR-based method of MUN 
measurement and the current gold standard enzymatic testing method (133).  
1.4.5.5. Urolithiasis 
Urolithiasis is a disorder most commonly treated in felids, canids, small 
ruminants and equids although it has been identified in a variety of other species 
including pigs, cattle, birds and turtles (135). The treatment and prevention of 
urolithiasis requires an in depth knowledge of both the composition and structure of the 
urinary calculi (136). As a result, various modalities, including IR spectroscopy, have 
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been utilized in recent years to better identify and study urinary calculi in canine, feline 
and equine species (136-139).  
Urinary calculi are composed of a variety of constituents, such as calcium 
carbonate, calcium oxalate, struvites, ammonium urate, etc., each of which can be 
differentiated by their distinctive absorption band within an IR spectra (137, 139). For 
example, research using IR spectroscopy to identify equine urinary calculi found 
characteristic bands for calcium carbonate at the 1500-1400 cm-1 region (138). As well, 
research looking at calculi in humans and dogs found calcium oxalate uroliths may be 
identified by the presence of strong absorption bands at 1320 cm-1 in the IR spectrum 
(137). These and other previous studies demonstrate the potential for IR spectroscopy 
to be used in a basic clinical setting to assist in the prevention and treatment of urinary 
calculi in companion animals and equids (136-138).  
1.4.6. Application of infrared spectroscopy in immunoglobulin quantification 
Recently, FTIR spectroscopy has been investigated for its ability to quantify 
immunoglobulins in the blood of both humans and horses (49, 140). To date, only two 
studies have used FTIR spectroscopy to measure IgG, IgA and IgM in human plasma, 
each with a different technique for Ig quantitation (107, 140). Of these studies, only one 
was fully validated and able to prove the reproducibility of its technique (140). In this 
study, IR spectroscopy was combined with partial least square regression to build and 
calibrate a model to predict the IgG, IgA and IgM concentrations from the spectra 
obtained from 90 samples of human plasma. Nephelometry was used as the gold 
standard reference method. Results demonstrated significant correlation between the 
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IR-predicted Ig concentrations and those obtained by nephelometry with R2 = 0.98 for 
IgA, R2 = 0.98 for IgG and R2 = 0.78 for IgM (140). Using various statistical methods, the 
authors were able to validate and prove the reproducibility of their IR-based technique 
for Ig quantitation as well as demonstrate the interchangeability of the FTIR and 
nephelometry techniques (140). 
A study evaluating the use of FTIR spectroscopy for the measurement of IgG 
concentrations in horses was also recently published (49). Similar to the aforementioned 
paper, partial least squares was used to successfully build an algorithm for the 
prediction of IgG concentrations from the IR spectra derived from equine serum 
samples. Validation of the algorithm was achieved through its ability to predict IgG 
concentrations based on the spectra produced from independent test sets of samples 
(49).  
1.5. Objectives of current study 
Based on the above proof of concept studies, it is hypothesized that FTIR 
spectroscopy may be a clinically useful tool for the measurement of IgG concentrations 
in camelid serum and Ig isotypes and subclasses in equine serum. More specifically, the 
objectives of the current research project include: 
1)  to develop an FTIR based assay for the measurement of IgG 
concentrations in alpaca serum and compare its performance to that of 
the current gold standard RID assay, and 
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2)  to develop FTIR based assays for the measurement of equine serum 
IgG(a), IgG(b), IgA, IgM and IgG(t) concentrations and compare their 
performance to that of the ELISA assay. 
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2.1. Abstract 
Background: Rapid, economical and quantitative assays for measurement of camelid 
serum immunoglobulin G (IgG) are limited. In camelids, failure of transfer of maternal 
immunoglobulins has a reported prevalence of up to 20.5%. An accurate method for 
quantifying serum IgG concentrations is required. 
Objectives: To develop an infrared (IR) spectroscopy-based assay for measurement of 
alpaca serum IgG and compare its performance to the reference standard radial 
immunodiffusion (RID) assay.  
Animals:  One hundred and seventy-five privately-owned, healthy alpacas. 
Methods:  Serum IgG concentrations were determined by RID assays and mid-IR spectra 
were collected for each sample. Fifty samples were set aside as the test set and the 
remaining 125 training samples were employed to build a calibration model using partial 
least squares (PLS) regression. The predictive performance of the calibration model was 
evaluated by the test set. 
Results: Correlation coefficients for the IR-based assay were 0.93 and 0.87, respectively, 
for the entire data set and test set. Sensitivity in the diagnosis of failure of transfer of 
passive immunity (FTPI) ([IgG] < 1000 mg/dl) was 71.4% and specificity was 100% for the 
IR-based method (test set) as gauged relative to the RID reference method assay. 
Conclusions and clinical importance: This study indicates that IR spectroscopy, in 
combination with chemometrics, is an effective method for IgG measurement in alpaca 
serum. 
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2.2. Introduction 
Pregnant camelids have an epitheliochorial form of placentation that unlike 
humans, does not allow for the in-utero transfer of immunoglobulins (Igs) (1). 
Consequently, newborn crias are born agammaglobulinemic and rely upon the transfer 
of maternal antibodies from the dam’s colostrum to acquire protective passive 
immunity for the first few weeks of life (2, 3). In the newborn cria, transfer of Igs is 
considered successful when immunoglobulin G (IgG) concentration in the serum is ≥ 
1000mg/dl (4). Failure to absorb sufficient amounts of Igs in the immediate post-partum 
period leads to a condition known as failure of transfer of passive immunity (FTPI) (1). 
FTPI has a reported prevalence between 9% and 20.5% in camelids and is recognized as 
an important disorder that might lead to an increased susceptibility to infectious 
organisms (4-7).  
The most common clinical reason for measuring camelid Igs is suspicion of FTPI, 
therefore early and accurate diagnosis is required to provide timely medical 
intervention (7). Testing methods available for use in camelids includes total serum 
protein and globulin concentration measurements, zinc sulphate turbidity, 
glutaraldehyde coagulation, sodium sulphate precipitation, immunoturbidimetric assay 
(TIA) and radial immunodiffusion (RID) (3, 4, 6, 8-11). Of these, RID provides quantitative 
data and is currently considered the reference method test for IgG quantification in 
various species (7). Notwithstanding the benefit of providing quantitative data, RID has a 
number of disadvantages including a substantial turnaround time of 18-24 hours for 
results, a requirement for enhanced technical skill by the user, high cost compared with 
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other testing methods and a requirement for specific reagents with a limited shelf-life 
(7, 9, 12). An accurate, more rapid and economic IgG assay for quantifying serum IgG is 
desirable for camelids. 
Fourier-transform infrared spectroscopy (FTIR) has emerged as a powerful 
diagnostic tool for quantitative and qualitative characterization of biological samples in 
human and veterinary medicine (13-15). The basis for this technique is that infrared 
radiation passing through a sample of interest is absorbed by that sample more or less 
strongly as a function of wavelength across the infrared spectral region. The resultant 
infrared absorption spectrum uniquely characterizes that sample, with the absorbance 
of radiation measured as a function of wavelength (μm) or wavenumber (cm-1), 
translating to absorption bands across the infrared spectrum (7, 14, 15). The infrared 
absorption patterns reflect the molecular composition of the sample (7). To the extent 
that molecular composition is characteristically affected by disease, the absorption 
patterns for biomedical specimens (biofluids and tissues) might be equated to 
biochemical “fingerprints”. These “fingerprints” then have the potential to correlate 
directly with the presence or absence of disease or provide the basis to quantify 
diagnostically pertinent biological fluid analytes (7). Thus, infrared spectroscopy could 
serve as a robust, reagent-free method to quantify certain biofluid components of 
diagnostic interest (7, 13, 14). If it were to prove sufficiently accurate, the ease of use 
and low cost per sample may make FTIR a desirable testing method for determining 
serum IgG concentrations.  
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The objective of this study was to develop a FTIR based assay for the 
measurement of IgG concentrations in alpaca serum and to compare its performance to 
that of the RID assay. 
2.3. Materials and Methods 
2.3.1. Experimental animals 
Serum samples collected from privately owned alpacas (n=175) between 2009 
and 2011 were used for this study. Eighty-two alpaca samples were from multiple farms 
located in Ontario and New Brunswick, Canada, while the remaining 93 were from 
properties in the Adelaide Hills region of South Australia. All alpacas were considered 
healthy based on general physical examination and no observable signs of disease. Age 
and gender was collected for 129 of the alpacas.  
2.3.2. Serum sampling protocol 
Blood samples were collected via jugular venipuncture in accordance with the 
University of Prince Edward Island’s Animal Care Committee animal utilization protocol 
and the Animal Ethics Committee of the University of Adelaide. Following collection, 
blood samples from Canada were centrifuged and the serum collected into a cryovial 
and frozen at -20°C until transported on ice by overnight courier to the Atlantic 
Veterinary College (AVC) where they were stored at -80oC prior to use. Blood samples 
collected in Australia were taken directly to a diagnostic laboratory for hematological 
analysis as part of a separate study. These samples were centrifuged and the serum 
collected and refrigerated at 4oC for 24-48 hours until biochemical analysis was 
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performed. The remaining serum was then stored frozen at -80OC prior to being 
couriered on ice to the AVC. 
2.3.3. Radial Immunodiffusion assay for immunoglobulin G antibodies 
Commercial RID assays (Triple J Farms; Bellingham, WA) were used as the 
reference method for determining IgG serum concentrations.  RID assays were 
performed according to manufacturer’s instructions.  The zones of precipitation 
diameters were read at 22-24 hours by the same individual to the nearest tenth of a 
millimetre using a handheld calliper. Samples exceeding the manufacturer’s stated 
upper testing limit (3000 mg/dL) were diluted with 0.85% saline and rerun. Each sample 
and standard was tested in replicates of five (one replicate per RID plate). The average 
of the 5 replicates of the assay standards were fitted by linear regression, and that 
equation was used to determine the concentration of IgG for the unknown serum 
samples. Regression equations for R2 >0.9 were accepted for analysis. The average of 
the 5 replicate results for each sample was used to determine the IgG concentration of 
that sample. 
2.3.4. Fourier-transform Infrared spectroscopy for immunoglobulin G 
antibodies 
Thawed serum samples were diluted 1:1 with a 4 g/L potassium thiocyanate 
solution. Following dilution, six replicate dry films were made for each serum sample by 
evenly spreading 12l aliquots of diluted sample onto 5-mm wells within a custom-
made, adhesive-masked, 96-well silicon microplate.(7) Each loaded microplate was 
allowed to dry at room temperature before being loaded into a multisamplera 
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interfaced with a FTIR spectrometerb and controlled with proprietary softwarec. 
Absorbance spectra in the IR range of 400-4000 cm-1 were recorded (resolution 4 cm-1, 
512 scans) for each replicate of each sample, using the single beam spectrum of an 
empty well as the background. 
2.3.5. Data processing 
Absorbance spectra were converted into printable format by GRAMS software 
packaged, then imported into MATLAB®e for further analysis. Calculations were 
performed using scripts written by the authors.  
A total of 1050 (175 samples x 6 replicates/sample) spectra were smoothed 
using the Savitzky-Golay method and processed by the standard normal variate 
transformation (16). This was followed by spectrum region selection chosen as 3700-
2600 cm-1 and 1800-1300 cm-1 (based on previous work for FTIR IgG analysis in horses 
and further refined to specific areas within those regions that exhibited strong signals) 
(7). With six replicate spectra per serum sample, spectrum outlier detection was carried 
out by using Dixon’s Q-test at each wavenumber with a confidence level set as 95% (18, 
19). Those spectra with over 50% of the absorbance values detected as outliers were 
excluded from further analysis. Outlier detection was performed for all the 175 serum 
samples. The spectra for each sample were then averaged and used for succeeding 
analysis. 
2.3.6. Calibration model development and assay validation 
A test set of spectra from serum samples (N=50) was randomly drawn from the 
pool of 175 samples and set aside for the purpose of later testing the predictive 
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performance of the calibration model. Spectra from the remaining samples (N=125) 
were again randomly split into a training set (N=75) and a validation set (N=50). Partial 
least squares (PLS) regression was applied to the training set to develop calibration 
models with the number of PLS factors ranging from 1 up to 50. This procedure (with 
new random training/validation splits for each trial, and the same test set throughout) 
was repeated 5000 times and the Monte Carlo Cross validation value (MCCV) was 
calculated by the equation  
2
1v
1
ˆMCCV=
N
i i
iNn 
 y y    
where N denotes the number of repeated procedures (N=5000), vn  is the number of 
samples in the validation set ( vn =50), and iy  and ˆ iy  represent the IgG concentrations 
for the samples, in the validation set, obtained from RID experiments and predicted 
from the IR spectroscopic data, respectively (20, 21). The number of PLS factors that 
gave the lowest MCCV value was chosen as the optimal value. Once the optimal number 
of PLS factors was determined, the training and validation sets were combined and the 
combined set was used to build a new calibration model. The predictive performance of 
the new calibration model was then evaluated by the test set that had been set aside in 
advance. The agreement among the RID and FTIR values for both the test set and 
combined data set was assessed by scatter plot, the Pearson correlation coefficient, and 
the concordance correlation coefficient. The differences between the RID and FTIR 
values for the test set was further characterized by the Bland-Altman plot and the 
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normal probability plot to further evaluate the model assumptions and performance 
(22). 
2.3.7. Precision of Fourier-transform infrared spectroscopic analyses 
With replicate spectra collected in this study, the precision of the FTIR method 
was evaluated based on the concentrations predicted for the test set samples/spectra. 
To that end, individual replicate spectra (not the averaged spectra) were used to 
calculate the IgG concentrations and the relative standard deviations (also called 
coefficient of variation) were used as the criteria to evaluate precision. For comparison, 
the relative standard deviation was also calculated for the individual replicate RID 
assays. 
2.3.8. Diagnostic sensitivity and specificity 
To assess potential applicability in the clinical diagnosis of FTPI (7), the diagnostic 
sensitivity and specificity of FTIR were calculated for the test set and entire data set 
using IgG <1000 mg/dl (based on RID) as the cut-off for a positive test for FTPI. 
2.4. Results 
2.4.1. Demographic data and RID-derived IgG concentration results 
Of the 129 alpacas for which signalment data were available, 81 were female 
and 48 were male. Four alpacas were <2 months of age, 5 were 2-3 months of age, 15 
were 3-6 months of age,  12 were between 6 months and 1 year of age and 93 were > 1 
year of age. Demographic data were unavailable for the remaining 46 alpacas. 
The RID IgG concentrations for the 175 serum samples ranged from 394 mg/dL 
to 6327 mg/dl.  Twenty-one samples had IgG concentrations below the 1000 mg/dl cut-
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off typically used to define FTPI in camelid neonates. Of the remaining 154 samples, 89 
had IgG concentrations between 1000 mg/dL and 3000 mg/dl and 65 had IgG 
concentrations >3000 mg/dL. 
2.4.2. Analysis of agreement between FTIR and RID IgG quantitation methods 
  The overall patterns for blood/serum/plasma infrared spectra are characterized 
by strong absorptions in two regions (3600-2750 cm-1 and 1800-400 cm-1), the former 
corresponding to stretching vibrations of the X-H moieties (X=C, N, O), and the latter 
corresponding to bending vibrations and stretching modes involving heavier atoms (e.g. 
the C=O stretch cited above) (Figure 2.1, page 86) (7). Within each spectrum, the most 
intense features result from proteins (the absorptions centering around 3300 cm-1 are 
attributed to N-H stretching and those around 1650 cm-1 correlate with C=O stretching 
of backbone protein amide linkages) (7). 
As a first step toward development of the IR-based analytical method, ten 
spectra were identified as outliers (using the method described above) and removed 
from further analysis. The PLS regression trials yielded an optimal model (based on the 
lowest MCCV) with 15 PLS factors.  A scatter plot (Figure 2.2, page 87) demonstrates the 
level of agreement between IgG concentrations obtained via RID and FTIR.  The Pearson 
correlation coefficients for the combined set (training and validation sets) and test set 
were 0.93 and 0.87, respectively. The concordance correlation coefficients were 0.93 
and 0.86, respectively (23, 24).  Both correlation coefficients indicated that the FTIR 
predicted IgG concentrations had good to excellent correlation with RID determined IgG 
concentrations. 
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The mean value of the differences (FTIR – RID) is -20.4 mg/dl, which is small 
compared to the IgG concentration values, indicating no significant systematic 
difference (bias) between the two methods (Figure 2.3, page 88). However, the 95% 
confidence intervals on the Bland-Altman plot indicated a high variability (standard 
deviation  600 mg/dl) between FTIR and RID methods. A normal probability plot for the 
differences (Figure 2.4, page 89) demonstrates the majority of data points are 
distributed closely around the reference line. No obvious non-normality was observed in 
the error distribution, indicating the model assumption was not violated and further 
validating the developed model.   
2.4.3. Precision of the FTIR Spectroscopic Analyses 
The relative standard deviations for the RID did not show an obvious correlation 
with the IgG concentration but the relative standard deviations for the FTIR method 
decreased with an increase of IgG concentration (Figure 2.5, page 90). The relative 
standard deviations for the RID and FTIR methods overlapped when the IgG 
concentration was high, but when the IgG concentration was low, the FTIR method had 
larger relative standard deviations. 
2.4.4. Diagnostic Sensitivity and Specificity 
For the test set (n=50), 7 samples had IgG concentrations below the 1000 mg/dl 
diagnostic cut-off value generating a FTPI prevalence of 14% in the test set. Sensitivity 
for this data set was 71.4% (95% confidence interval (95%CI) = 30.3-94.9) and specificity 
was 100% (95% CI = 89.8-100).  Using the entire data set (n=175; 21 samples with IgG 
concentrations below 1000 mg/dl), sensitivity was 81% (95% CI = 57.4-93.7) and 
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specificity was 100% (95% CI = 97-100). Within the entire data set, there were no false 
positives and 4 false negatives identified (Table 2.1, page 85). 
2.5. Discussion 
This study showed that infrared spectroscopy, in combination with a 
quantification algorithm developed using PLS regression, is a promising technique for 
the measurement of IgG concentrations in camelid serum. This method was validated by 
its ability to accurately quantify IgG concentrations in an independent test set of 
samples.     
Within this study the specificity was excellent but the sensitivity of the FTIR 
method was slightly lower than desired for diagnosis of FTPI in neonates. However, 
when compared with reported data for other methods available to quantify camelid 
serum IgG concentrations, these results are equivalent to or better than most (3, 6). One 
study looked at using a commercially available sodium sulphate turbidity test for the 
diagnosis of FTPI in crias. The authors found that when compared with RID and used 
according to manufacturer’s instructions, the sensitivity for this test was only 36% and 
specificity was 100% (6). However, they also noted that by lowering the test’s endpoint, 
the performance of the test could be significantly improved (6). The same study also 
found that serum total protein concentration, at an endpoint of 5.0 g/dl, yielded a 
sensitivity of 71% and specificity of 80% and that serum globulin concentration, at an 
endpoint of 2.5 g/dl, produced a sensitivity of 64% and specificity of 100% when 
compared with RID (6). The authors concluded that measurement of serum albumin, 
total solids or gamma-glutamyltransferase activity were not predictive of FTPI in crias 
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(6). Other researchers have found that total serum protein measurement, at an 
endpoint of 5.15 g/dl, had a sensitivity of 87.5% and specificity of 87.9% when compared 
with RID (3). Serum globulin concentration, at and endpoint of 1.6 g/dl, had a test 
sensitivity of 96.1% and specificity of 91.2% when compared with RID (3). This study also 
compared zinc sulphate turbidity and 10% glutaraldehyde coagulation tests with RID 
and found sensitivities of 100% and 78.4%, respectively, and specificities of 54.3% and 
91.2% for these testing methods (3).   
A recent study of the diagnostic agreement between the currently available 
camelid RID kit and 2 new commercially available turbidimetric immunoassay (TIA) 
assays found a lack of agreement between the 3 methods with the significant 
differences between assay results mainly attributed to their use of different standards 
(11). Of the 3 assays, RID was found to be the most imprecise leading the authors to 
question if the RID assay should continue as the “gold standard” for camelid serum IgG 
quantification or whether a more automated and precise method, such as TIA, should 
be adopted (11). These considerations raise an important question relevant to the 
present study: Might the accuracy of the FTIR-based assay be improved if a TIA assay 
was used as the reference standard rather than the RID assay? This issue is potentially 
worth exploring in future studies. However it must be emphasized that imprecision does 
not equate with inaccuracy and that the above referenced study did not determine the 
accuracy of the RID and TIA assays - only their precision and agreement.  
Overestimation of IgG concentrations (false negatives) is a problem sometimes 
encountered with testing methods such as the zinc sulphate turbidity or the 
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glutaraldehyde coagulation test (25). With these tests, chemical interference from other 
proteins, such as albumin or hemoglobin, may occur resulting in inaccurate results (7). 
These erroneous test results can have clinical consequences for the neonate in question, 
including an increased risk of pneumonia, septicaemia, enteritis, omphalitis and death, if 
no medical treatment is provided due to a false negative test result (4).  With FTIR the 
possibility for chemical interference can be reduced by ensuring that potential 
interferants are accounted for within the spectral data set used to develop the 
diagnostic algorithms (7).  Within the test set of this study, 4 false negatives were 
identified. Upon gross examination of the serum samples, no hemolysis or lipemia was 
noted indicating interference from these components was not a major factor with these 
samples.  
For the 4 false negatives within our data set, the RID-derived IgG concentrations 
were >700 mg/dL indicating only partial FTPI in these cases. Studies have shown that 
foals with serum IgG concentrations <400 mg/dl (complete FTPI) are at a significantly 
greater risk of developing septicaemia and other debilitating diseases, however, no 
similar association has been shown in foals with partial FTPI (serum IgG concentrations 
between 400-800 mg/dL) (26-28). While comparable studies have not been performed in 
camelid species, it is reasonable to assume that those crias with very low or complete 
FTPI may have an increased risk of morbidity and mortality when compared to crias with 
only partial FTPI. Accordingly, while the false negatives in this FTIR study are an issue, 
the partial FTPI concentrations were less likely to result in serious clinical consequences. 
We also note that discrepancies between concentrations determined by IR spectroscopy 
79 
 
and RID may arise from errors in the RID method; it is possible that better reference 
measurements would resolve the apparent discrepancies and reduce the apparent false 
negative rate accordingly.  
A drawback of this study is the relatively small number of serum samples with 
low IgG concentrations in the data set. This limitation led to only 21 of the 175 samples, 
a 12% prevalence, having a serum IgG concentration below the 1000 mg/dl cut-off with 
only 7 of those 21 randomly assigned into the test set. As a result, the small number of 
samples with IgG concentrations <1000 mg/dl may affect the algorithm’s accuracy in 
predicting IgG values at lower concentrations as algorithm development was weighted 
toward higher IgG concentrations. In future studies, it would be desirable to obtain 
another data set with a higher proportion of samples with IgG concentrations <1000 
mg/dl, which would allow further modification of the algorithm and possibly better 
performance at lower IgG concentrations.  
A variety of previous studies have demonstrated the potential for FTIR in a 
clinical laboratory setting (29, 30). The unique absorption pattern displayed for each 
unique analyte allows for the possibility to distinguish among different sample 
components and separately quantify them, thus providing additional useful clinical data 
(29, 30). For example, at least six serum constituents of importance in both veterinary 
and human medicine have been proven suitable for FTIR based analysis in prior studies. 
These include total protein, albumin, glucose, triglycerides, urea and cholesterol (29, 30). 
Consequently, it might be possible to acquire extra clinical pathological data from each 
spectrum without further time requirements or additional costs (7). In addition to 
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diagnosing FPT or measuring serum constituents, FTIR may also prove useful in both a 
clinic or laboratory setting to quantify IgG in adult camelid plasma donors. 
In conclusion, Fourier-transform infrared spectroscopy is a promising technique 
to rapidly quantify IgG concentrations in alpaca serum. Further studies with a larger 
data set of low IgG serum concentrations are warranted to further refine the algorithm 
for screening cria’s with FTPI. 
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2.6. Footnotes 
a HTS-XT autosampler, Bruker Optics®, Milton, ON, Canada 
b Tensor 37, Bruker Optics®, Milton, ON, Canada 
c OPUS® ver. 6.5, Bruker Optics®, Milton, ON, Canada 
d GRAMS software ver. 7.02, Thermo Fisher Scientific Inc, Waltham, MA, USA 
e MATLAB MathWorks R2011b, Natick, MA, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
2.7. Acknowledgments 
The authors would like to gratefully acknowledge Cynthia Mitchell for her 
technical assistance and Professor Michael Reichel for providing some of the samples 
used in this study.  
Funding for this project was supported by the Atlantic Canada Opportunities 
Agency and the Atlantic Veterinary College Research Fund. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
2.8. References 
 1. Chappuis G. Neonatal immunity and immunisation in early age: Lessons from veterinary 
medicine. Vaccine. 1998;16:1468-1472.  
2. Garmendia AE, Palmer GH, DeMartini JC, McGuire TC. Failure of passive immunoglobulin 
transfer: A major determinant of mortality in newborn alpacas (lama pacos). Am J Vet Res. 
1987;48:1472-1476.  
3. Drew ML, Fowler ME. Comparison of methods for measuring serum immunoglobulin 
concentrations in neonatal llamas. J Am Vet Med Assoc. 1995;206:1374-1380.  
4. Wernery U. Camelid immunoglobulins and their importance for the new-born--a review. J Vet 
Med B Infect Dis Vet Public Health. 2001;48:561-568.  
5. Weaver DM, Tyler JW, Scott MA, Wallace LM, Marion RS, Holle JM. Passive transfer of 
colostral immunoglobulin G in neonatal llamas and alpacas. Am J Vet Res. 2000;61:738-741.  
6. Weaver DM, Tyler JW, Marion RS, Wallace LM, Nagy JK, Holle JM. Evaluation of assays for 
determination of passive transfer status in neonatal llamas and alpacas. J Am Vet Med Assoc. 
2000;216:559-563.  
7. Riley CB, McClure JT, Low-Ying S, Shaw RA. Use of fourier-transform infrared spectroscopy for 
the diagnosis of failure of transfer of passive immunity and measurement of immunoglobulin 
concentrations in horses. J Vet Intern Med. 2007;21:828-834.  
8. Bravo P, Garnica J, Fowler M. Immunoglobulin G concentrations in periparturient llamas, 
alpacas and their crias. Small Ruminant Research. 1997;26:145-149.  
9. Hutchison JM, Salman MD, Garry FB, Johnson LW, Collins JK, Keefe TJ. Comparison of two 
commercially available single radial immunodiffusion kits for quantitation of llama 
immunoglobulin G. J Vet Diagn Invest. 1995;7:515-519.  
10. Johnston NA, Parish SM, Tyler JW, Tillman CB. Evaluation of serum gamma-
glutamyltransferase activity as a predictor of passive transfer status in crias. J Am Vet Med 
Assoc. 1997;211:1165-1166.  
11. Pinn TL, Gagliardo LF, Purdy SR, Appleton JA, Stokol T. Comparison of three immunoglobulin 
G assays for the diagnosis of failure of passive transfer of immunity in neonatal alpacas. Journal 
of Veterinary Diagnostic Investigation. 2013;25:91-98.  
12. Davis R, Giguere S. Evaluation of five commercially available assays and measurement of 
serum total protein concentration via refractometry for the diagnosis of failure of passive 
transfer of immunity in foals. J Am Vet Med Assoc. 2005;227:1640-1645.  
84 
 
13. Benezzeddine-Boussaidi L, Cazorla G, Melin AM. Validation for quantification of 
immunoglobulins by fourier transform infrared spectrometry. Clin Chem Lab Med. 2009;47:83-
90.  
14. Vijarnsorn M, Riley CB, Shaw RA, et al. Use of infrared spectroscopy for diagnosis of 
traumatic arthritis in horses. Am J Vet Res. 2006;67:1286-1292.  
15. Vijarnsorn M, Riley CB, Ryan DAJ, Rose PL, Shaw RA. Identification of infrared absorption 
spectral characteristics of synovial fluid of horses with osteochondrosis of the tarsocrural joint. 
Am J Vet Res. 2007;68:517-523.  
16. Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares 
procedures. Anal Chem. 1964;36:1627-1639.  
17. Barnes RJ, Dhanoa MS, Lister SJ. Standard normal variate transformation and de-trending of 
near-infrared diffuse reflectance spectra. Appl Spectrosc. 1989;43:772-777.  
18. Dean RB, Dixon WJ. Simplified statistics for small numbers of observations. Anal Chem. 
1951;23:636-638.  
19. Rorabacher DB. A statistical treatment for rejection of deviant values: Critical values of 
dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem. 
1991;63:139-146.  
20. Picard RR, Cook RD. Cross -validation of regression models. J Amer Statist Assn. 1984;79:575-
583.  
21. Xu QS, Liang YZ. Monte carlo cross validation. Chemom Intell Lab Syst. 2001;56:1-11.  
22. Altman DG, Bland JM. Measurement in medicine: The analysis of method comparison 
studies. Statistician. 1983;32:307-317.  
23. Lin LI. A concordance correlation coefficient to evaluation reproducibility. Biometrics. 
1989;45:255-268.  
24. Steichen TJ, Cox NJ. A note on the concordance correlation coefficient. Stata J. 2002;2:183-
189.  
25. Clabough DL, Conboy HS, Roberts MC. Comparison of four screening techniques for the 
diagnosis of equine neonatal hypogammaglobulinemia. J Am Vet Med Assoc. 1989;194:1717-
1720.  
26. Clabough DL, Levine JF, Grant GL, Conboy HS. Factors associated with failure of passive 
transfer of colostral antibodies in standardbred foals. J Vet Intern Med. 1991;5:335-340.  
27. LeBlanc MM, Tran T, Baldwin JL, Pritchard EL. Factors that influence passive transfer of 
immunoglobulins in foals. J Am Vet Med Assoc. 1992;200:179-183.  
85 
 
28. McClure JT, DeLuca JL, Lunn DP, Miller J. Evaluation of IgG concentration and IgG subisotypes 
in foals with complete or partial failure of passive transfer after administration of intravenous 
serum or plasma. Equine Vet J. 2001;33:681-686.  
29. Shaw RA, Low-Ying S, Leroux M, Mantsch HH. Toward reagent-free clinical analysis: 
Quantitation of urine urea, creatinine, and total protein from the mid-infrared spectra of dried 
urine films. Clin Chem. 2000;46:1493-1495.  
30. Low-Ying S, Shaw RA, Leroux M, Mantsch HH. Quantitation of glucose and urea in whole 
blood by mid-infrared spectroscopy of dry films. Vibrational Spectroscopy. 2002;28:111-116.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
Table 2.1 
FTIR IgG false negative samples compared to IgG RID results identified within the entire 
data set (n =175). 
Sample Data Set FTIR IgG Value (mg/dL) RID IgG Value (mg/dL) 
A Calibration 1075 719 
B Calibration 1192 773 
C Test 1602 861 
D Test 1307 822 
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Figure 2.1 Representative infrared spectrum of alpaca serum. The strongest features 
arise from proteins with relatively less abundant serum components contributing 
relatively weak fingerprints. The absorption at 2062 cm-1 originates with the KSCN- 
internal standard. 
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Figure 2.2 A scatter plot comparing the IgG concentrations obtained from RID and FTIR 
methods. The asterisks denote samples used in building the calibration model and the 
circles indicate the samples in the test set. If RID and FTIR give comparable results, the 
data points should distribute closely around the reference line of 45o. 
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Figure 2.3 A Bland-Altman plot of the differences in the IgG concentrations in the test 
set as obtained by RID and FTIR methods. The solid horizontal line represents the mean 
difference between RID and FTIR assays (-20.4 mg/dl) and the dashed lines represent 
the 95% confidence interval. If there is no systematic bias between RID and FTIR 
method, the mean value of the differences should be close to zero.  
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Figure 2.4 Normal probability plot for the differences of the IgG concentrations in test 
set obtained from RID and FTIR methods. If the measurement errors follow a normal 
distribution, the data points should be largely located in the reference line.  
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Figure 2.5 Coefficient of variance plots for the RID and FTIR methods. Lower coefficient 
of variance means high precision of the test methods; this comparison shows that the 
precision of the RID and FTIR methods are rougly comparable. 
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CHAPTER 3 
EXPLORATORY STUDY EVALUATING THE USE OF FOURIER TRANSFORM INFRARED 
SPECTROSCOPY FOR THE QUANTITATION OF IMMUNOGLOBULIN ISOTYPES IgA and 
IgM AND IgG SUBCLASSES (IgGa, IgGb, IgG(T)) IN EQUINE PLASMA 
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3.1. Abstract 
Studies investigating the measurement of immunoglobulin G (IgG) subclasses 
(IgGa, IgGb, IgG(T)), immunoglobulin A (IgA) and immunoglobulin M (IgM) in adult 
equine plasma are scarce in current literature, and poor agreement is noted among 
the results of published studies. Previous studies have shown that Fourier-transform 
infrared (FTIR) spectroscopy can be used to measure IgG concentrations in horse 
plasma. Therefore, FTIR spectroscopy may be a promising new method for the 
quantification of Ig isotypes and IgG subclasses in equine plasma. The first objective of 
this study was to determine adult equine plasma IgGa, IgGb, IgG(T), IgA, and IgM 
concentrations using an enzyme-linked immunosorbent (ELISA) assay and to compare 
the results to previous studies. The second objective was to develop FTIR based assays 
for the measurement IgGa, IgGb, IgG(T), IgA, and IgM in equine plasma using the ELISA 
results as the reference test. 
Immunoglobulin Ga, IgGb, IgG(T), IgA, and IgM concentrations were determined 
by ELISA assays and mid-infrared spectra were collected for 100 equine plasma samples. 
After preliminary assessment 99 spectra met the criteria for use in model building and 
were randomly divided into a training set (N=60 sera) and prediction set (N=39 sera). 
The training set was used to build a calibration model for each Ig isotype or subclass 
using partial least squares (PLS) regression. The 39 samples in the prediction set were 
then used to test the predictive performance of the developed models. 
Mean serum concentrations (± standard deviation, g/L) determined via ELISA 
assay were 2.72 ± 0.77 for IgGa, 9.21 ± 2.47 for IgGb, 4.96 ± 2.35 for IgG(T), 1.01 ± 0.76 
94 
 
for IgA and 0.79 ± 0.31 for IgM. Pearson correlation coefficients and scatter plots 
displayed moderate to good agreement between FTIR and ELISA IgGb results in the 
training and prediction data sets. For IgGa, IgG(T) IgA and IgM, Pearson correlation 
coefficients and scatter plots displayed moderate to extremely poor agreement 
between FTIR and ELISA results in the training and prediction data sets.  
In this study an infrared spectroscopic assay was not an accurate technique for 
the measurement of Ig isotypes in equine plasma. Significant differences were noted 
between the results of this study and each of the reviewed studies from the published 
literature. Further work is required to establish normal reference ranges for Ig isotypes 
and subclasses in adult equine plasma. 
3.2. Introduction  
Primary immunodeficiency disorders in equids, although uncommon, can be 
difficult to identify and often result in unfavorable outcomes (1). Recognised primary 
immunodeficiency syndromes in horses include severe combined immunodeficiency 
disorder (SCID), selective immunoglobulin M (IgM) deficiency, foal immunodeficiency 
syndrome (FIS) and agammaglobulinemia (1-3). Due to the potentially life-threatening 
consequences of these disorders, researchers have studied their pathogenesis, 
diagnosis, treatment and prognosis (4, 5). For many of these equine 
immunodeficiencies, diagnosis is based in part, or entirely, on the measurement of 
specific immunoglobulin (Ig) concentrations in serum (6). As a result, numerous testing 
methods have been developed for the rapid quantification of Igs in equine serum, with 
the majority focusing on the measurement of immunoglobulin G (IgG) (7-12).   
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Studies investigating the measurement of Ig isotypes (other than IgG) or IgG 
subclasses in adult horses are scarce in current literature (13). Most studies 
investigating the equine humoral immune response have concentrated on the pre- and 
post-parturient period in mares and foals (13, 14). As a result, secondary 
immunodeficiencies such as failure of transfer of passive of immunity (FTPI) are easily 
recognized and treated, with various methods for IgG measurement readily available 
to aid in diagnosis (1). However, as certain primary immunodeficiencies result either 
entirely or in part from an Ig deficiency other than IgG, methods to quantify other Ig 
isotypes are required (15).  
The most abundant Ig found in equine plasma is IgG (16). Currently, seven well-
characterized IgG subclasses have been identified in equine plasma, including IgGa (IgG1 
and IgG2), IgGb (IgG4), IgGc (IgG6 and IgG7)and IgG(T) (IgG3 and IgG5) (17, 18). In addition 
to IgG, other isotypes that participate in equine immunity include immunoglobulin A 
(IgA), immunoglobulin M (IgM), immunoglobulin D (IgD) and immunoglobulin E (IgE) (4). 
Research investigating the measurement of these Ig isotypes and IgG subclasses in adult 
horse plasma is scarce. A review of current literature identified only a handful of studies 
where the primary objective was to establish normal ranges for IgM, IgA or IgG 
subclasses in adult horse serum using either radial immunodiffusion (RID) or enzyme-
linked immunosorbent (ELISA) assays (13, 19-21). These papers represent the majority 
of recent work investigating the measurement of Ig isotypes (other than IgG) or IgG 
subclasses in adult horses, however, significant discrepancies were noted among their 
96 
 
results. Therefore, further studies are required to establish normal reference ranges for 
Ig isotypes and IgG subclasses in adult plasma (13, 19-21).  
At present, RID assays are no longer commercially available for equine Ig isotype 
quantitation other than IgG or IgM. As a result, ELISA assays are one of the only 
remaining commercial methods for this purpose. However, ELISAs suffer from a number 
of disadvantages including the use of temperature and contamination sensitive reagents 
and a higher cost per test than other screening methods, particularly when only a few 
samples are assayed at one time (5).  Therefore, a rapid, accurate and cost-effective 
assay is required for the measurement of Ig isotypes and IgG subclasses in equine 
serum.  
In the past decade, Fourier-transform infrared (FTIR) spectroscopy has emerged 
as a powerful diagnostic tool for the quantitative characterization of biological fluids in 
both human and veterinary medicine (5, 22-24). In particular, FTIR spectroscopy has 
proven to be an accurate, economical and reagent-free method for equine IgG 
quantitation in foal serum and adult equine plasma samples (5, 25). Based on these 
successful proof-of-concept studies for IgG measurement in equids, it would seem 
plausible that infrared spectroscopy may also serve as a promising new method for the 
quantification of other Ig isotypes and IgG subclasses in equine plasma. 
The first objective of this study was to determine adult equine plasma IgGa, 
IgGb, IgG(T), IgA, and IgM concentrations using an ELISA assay and to compare these 
results to previous studies using the ELISA assay, as well as to compare the sum of IgGa, 
IgGb, and IgG(T) results to the total IgG concentrations found in horses included in the 
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study. The second objective was to develop FTIR based assays for the measurement 
IgGa, IgGb, IgG(T), IgA, and IgM for equine plasma using the ELISA results as the 
reference test. 
3.3. Materials and methods 
3.3.1. Experimental animals & sample collection 
This study was carried out in accordance with the University of Prince Edward 
Island’s Animal Care Committee animal utilization protocol. Plasma samples were 
collected from 100 healthy adult horses. All horses were a part of a closed herd that was 
privately owned by a commercial equine plasma company (Lake Immunogenics Inc., 
located in Ontario, New York, USA). Blood samples were collected by company 
employees from donor horses via jugular venipuncture using sodium citrate as the 
anticoagulant. Samples were collected in compliance with a New York State permit for 
the use of living animals and a United States Department of Agriculture research license. 
Samples were frozen and shipped on dry ice to the Atlantic Veterinary College (AVC) 
where they were stored at -80oC. All samples were used in a separate study at the AVC 
prior to use in the current study and were stored at -80oC for the duration between 
studies (25).  
3.3.2. Enzyme-linked immunosorbant assays for equine plasma IgG 
subclasses, IgM and IgA 
3.3.2.1.  Plasma sample dilutions 
To ensure plasma sample concentrations fell within a specific range, as per the 
manufacturer’s instructions, plasma samples were diluted prior to their use in the 
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commercial ELISA kits (Bethyl Laboratories Inc.; Montgomery, TX). Dilution factors were 
determined using the expected concentrations of the immunoglobulin isotype to be 
measured (obtained from the literature) (13, 21) and the manufacture stated 
concentration range limits of the different ELISA kits (200 – 3.12 ng/ml for IgGa and IgGb 
and 1000 – 15.6 ng/ml for the IgG(T), IgM and IgA kits). The dilution factor that would 
theoretically allow the results to best fall within the middle of the concentration range 
for each ELISA kit was employed. For example, the IgGb concentration range in the 
literature is 7.8 – 35.5 x 106 ng/ml (21). Using 20 x 106 ng/ml as the median expected 
IgGb concentration to be measured, it was calculated that a dilution factor of 1:200,000 
would allow the sample results to fall within the centre (i.e., 100 ng/ml) of our standard 
curve. Using the same calculation method for the other isotypes or IgG subclasses, 
dilution factors of 1:40,000 for IgGa, 1:8,000 for IgG(T), 1:3,000 for IgA and 1:2,000 for 
IgM were obtained. These dilutions were adequate for IgGa, IgGb, IgA and IgM. 
However, IgG(T) required further dilution to 1:15,000 to allow all serum samples  to fall 
within the standard range of the test kit. 
3.3.2.2. Standard dilutions 
A set of eight standards were prepared in accordance with the manufacturer’s 
instructions for each ELISA kit (see APPENDIX A, section 1 for details).  The eight 
standard concentrations varied depending on the specificity of each ELISA. For the 
IgG(T), IgA and IgM ELISA quantitation kits, the standard concentrations were 1,000 
ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml and 0 
ng/ml. For the IgGa and IgGb ELISA quantitation kits, the standard concentrations were 
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200 ng/ml, 100 ng/ml, 50 ng/ml, 25 ng/ml, 12.5 ng/ml, 6.25 ng/ml, 3.12 ng/ml and 0 
ng/ml. 
3.3.2.3. Detection antibody dilutions 
The manufacturer-supplied detection antibody was a horseradish peroxidase 
(HRP) conjugated polyclonal immunoglobulin (specific to each kit). Detection antibody 
dilutions were prepared for use in the individual ELISAs as per manufacturer’s 
instructions (see APPENDIX A, section 2 for details). Recommended starting dilutions 
were provided for each kit with instructions to increase or decrease the detection 
antibody dilution if the optical density (OD) value for the highest standard was above or 
below the required range of 1.8-2.2. Recommended starting dilutions were 1:75,000 for 
IgG(T), 1:60,000 for IgGb, 1:35,000 for IgGa, 1:35,000 for IgM and 1:100,000 for IgA. 
With the exception of IgG(T) and IgA, these recommended starting dilutions were 
inadequate to maintain the OD value of the highest standard within the required 1.8-2.2 
range. To resolve this issue, multiple trials investigating different detection antibody 
dilutions were performed for IgGa, IgGb and IgM to identify the optimal detection 
antibody concentration for each of these three Ig isotypes/subclasses (see APPENDIX A, 
section 3 for details). Final dilutions of 1:42,000 for IgGa, I:65,000 for IgGb and 1:45,000 
for IgM were used in this study.  
3.3.2.4. Procedure overview 
For each isotype or IgG subclass, all 100 samples were run simultaneously by a 
single operator. Using the previously determined serum, standard and detection 
antibody dilutions for each antibody isotype or subclass, commercially available ELISA 
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kits were used according to the manufacturer’s instructions (Bethyl Laboratories Inc.; 
Montgomery, TX). Briefly, 100µl of diluted coating antibody was added to each well of a 
96-well microplate and incubated at room temperature (20-25oC) for one hour. After 
incubation, plates were washed five times (with a Tris-saline wash buffer containing 
0.05% Tween) using an automated washerd. All wells were then blocked with 200ul/well 
of blocking solution containing the basic wash solution (without Tween) plus 1% BSA for 
30 minutes at room temperature. Plates were washed five times. Next, 100µl of diluted 
sample (n=100) or standard were added to duplicate wells and allowed to incubate at 
room temperature for one hour.  Following incubation, plates were washed five times 
and 100µl of diluted HRP conjugated detection antibody was added to each well and 
allowed to incubate at room temperature for one hour. Plates were then washed five 
times and 100µl of tetramethylbenzidine (TMB) substrate solution was added to each 
well and incubated for 15 minutes at room temperature in the dark.  The reaction was 
stopped by adding 100µl of stop solution (0.18M H2SO4) to each well. The absorbance of 
each well was measured on an ELISA microplate readere at a wavelength of 450 nm. The 
microplate reader was interfaced with a software programf that created a standard 
curve for each plate from which the serum Ig isotypes or subclasses concentrations 
were derived. 
3.3.3. Radial immunodiffusion assays for equine plasma IgG 
Commercial RID assays (Triple J Farms; Bellingham, WA) were used as the 
reference method for determining total IgG plasma concentrations.  RID assays were 
performed according to manufacturer’s instructions and all samples were diluted 1:1 
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with sterile saline. The zones of precipitation diameters were read at 22-24 hours by a 
single operator to the nearest tenth of a millimetre using a handheld calliper. Each 
sample and standard was tested in replicates of five. The average of the 5 replicates of 
the assay standards were fitted by linear regression, and that equation was used to 
determine the concentration of IgG for the unknown serum samples. The average of the 
5 replicate results for each sample was used to determine the IgG concentration of that 
sample.  
3.3.4. Fourier-transform infrared spectroscopy for immunoglobulin isotypes 
and IgG subclasses  
Thawed plasma samples were diluted 1:1 with a 4 g/L potassium thiocyanate 
solution. Following dilution, dry films were made for each serum sample by evenly 
spreading 8l aliquots of diluted sample onto 5-mm wells within a custom-made, 
adhesive-masked, 96-well silicon microplate.(5) Twelve sample replicates were made for 
sample 1 – 63, while 6 sample replicates were made for samples 64 – 100. Each loaded 
microplate was allowed to dry at room temperature before being loaded into a 
multisamplera interfaced with a FTIR spectrometerb and controlled with proprietary 
softwarec. Absorbance spectra in the infrared (IR) range of 400-4000 cm-1 were recorded 
(resolution 4 cm-1, 512 scans) for each replicate of each sample, using the single beam 
spectrum of an empty well as the background. These spectral parameters were utilized 
in a previous study (25).  
3.3.5. Data processing and algorithm development 
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The data set for each Ig isotype (IgGa, IgGb, IgG(T), IgA and IgM) was processed 
and analysed separately using the same methods as outlined below. For each of the 100 
serum samples, absorbance spectra in the IR range of 400-4000 cm-1 were converted 
into printable format by GRAMS software packageg, then imported into MATLAB®h for 
further analysis. 
A total of 978 spectra (63 samples x 12 replicates + 37 samples x 6 replicates) 
were processed using the Savitzky-Golay method to smooth the spectra and standard 
normal variate transformation to reduce the effect of light scattering and baseline 
variations (26, 27). Spectrum region selections at 3700-2600 cm-1 and 1800-1300cm-1 
were chosen based on earlier work at the using FTIR spectroscopy for IgG analysis in 
horses (5). The spectra for each sample were then averaged and used for succeeding 
analysis. 
Using Dixon’s Q-test, one sample was identified and removed as an outlier, 
leading to spectra from 99 samples used in further analysis (28). For each of the five 
isotype data sets, the spectra were divided into a training set (N=60 sera) and prediction 
set (N=39 sera). Partial least squares (PLS) regression was employed to build the 
calibration model (29). To determine the number of PLS factors in PLS regression, the 
training set was further randomly split into two sets of equal size (N=30 each). The first 
set was used to build a model with the number of PLS factors chosen from 1 to 30 and 
the second set was used to calculate the sum of squares of the difference between the 
Ig values from FTIR and ELISA. This procedure was repeated 5,000 times. The number of 
PLS factors was chosen as the one giving the lowest Monte Carlo cross validation value 
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(see equation in Chapter 2, page 72). Once the number of PLS factors were determined, 
the whole training set was used to develop a calibration model for each Ig isotype or 
subclass. Then 39 samples in the prediction set were used to test the predictive 
performance of the developed models.  
3.3.6. Statistical analysis of ELISA-derived Ig concentrations 
Agreement between the ELISA and FTIR generated Ig concentrations for each 
isotype in the training and prediction sets was assessed by scatter plot and the Pearson 
correlation coefficient. 
Descriptive statistics (mean + standard deviation [SD]) for each data set were 
calculated using a computer-based statistical software programi. Comparisons between 
ELISA Ig isotype concentration results in this study and those in current literature were 
performed using two-sample t-tests. Results with p ≤ 0.05 were considered significant. 
For comparison with the present study, standard deviations were calculated for results 
in the literature which only provided the standard margin of error (SEM) using the 
equation SD = √n * SEM, where n = sample size.  
The mean RID IgG concentration for the 100 equine plasma samples was 
compared to the mean ELISA total IgG concentration (obtained by summing the IgGa, 
IgGb and IgG(T) concentrations for each sample then acquiring the mean of these 
results) using a two-sample t-test (p ≤ 0.05). 
3.3.7  Nanosep® centrifugal filtration device trials for the removal of albumin 
from equine plasma samples 
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Following the above procedures, trials were conducted using Nanosep® 100K 
centrifugal filter devices (Pall Life Sciences; Ann Arbor, MI) in an attempt to increase the 
relative concentration of Ig isotypes and subclasses in equine plasma by removing 
albumin from the sample. Full details of these trials are outlined in APPENDIX B. In brief, 
multiple trials were performed according to the manufacturer’s instructions using 
various plasma starting volumes, plasma dilutions and filter washing techniques. Visual 
examination of the resulting spectra, and comparison of these to the original un-filtered 
spectra, was used to determine whether albumin was successfully removed from the 
plasma samples. Visual examination of the filtrate spectra was also performed to 
identify whether albumin had in fact passed through the membrane into the filtrate.  
3.4. Results 
Serum concentrations (g/L) ranged from 1.31 – 5.05 for IgGa, 5.45 – 19.85 for 
IgGb, 1.59 – 16.69 for IgG(T), 0.18 – 7.04 for IgA and 0.25 – 1.65 for IgM. Table 3.1 (page 
120) displays the mean serum immunoglobulin concentrations of IgGa, IgGb, IgG(T), IgA 
and IgM found in this study, as well as those from previously published studies for 
comparison (13, 19-21). No significant differences were noted between the IgG(T) and 
IgM results in this study and those of de Camargo et al., yet significant differences were 
observed between IgA concentrations (13). The IgGa and IgG(T) concentration results of 
Sheoran et al. were similar to those calculated in this study, yet their IgGb and IgA 
concentrations differed significantly (21). Results of this study were all significantly 
different from those found in the studies by McFarlane et. al. and Holznagel et al. (19, 
20). 
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The RID IgG concentrations for the 100 plasma samples ranged from 17.98 g/L to 
53.14 g/L with a mean and standard deviation [SD] of 30.98 ± 8.25 g/L. The sum of the 
IgGa, IgGb and IgG(T) ELISA concentrations for the 100 plasma samples ranged from 
11.65 g/L to 28.56 g/L with a mean (± SD) of 16.90 ± 3.54 g/L. T-test results indicate the 
two data sets are statistically different (p=0.000) from one another.  
The PLS regression trials yielded a model with 20 PLS factors for each of the Ig 
isotypes. In the training data sets, the Pearson correlation coefficients comparing the 
ELISA and FTIR-derived IgGa, IgGb, IgG(T), IgM and IgA  concentrations were 0.55, 0.89, 
0.88, 0.66 and 0.62, respectively. These results indicate that the FTIR predicted IgGb and 
IgG(T) concentrations in the training set had good correlation with their ELISA 
determined counterparts. The FTIR predicted IgGa, IgM and IgA concentrations in the 
training set exhibited poor correlation with their corresponding IgGa, IGM and IgA 
ELISA-determined concentrations.  
In the prediction data sets, the Pearson correlation coefficients for the IgGa, 
IgGb, IgG(T), IgM and IgA  results were 0.46, 0.71, 0.24, 0.27 and 0.09, respectively. 
These findings reveal that the FTIR predicted concentration values for each of the Ig 
isotypes in the prediction set had poor correlation with their corresponding ELISA-
determined concentrations, with the exception of IgGb, which demonstrated moderate 
correlation. Scatter plots (Figures 3.1-3.5, pages 121-125) further show the findings of 
the Pearson correlation coefficients.  
The full details of the results for the filtration trails are outlined in APPENDIX B. 
However, the key finding was that upon visual examination of the spectra obtained from 
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the fluid remaining in the sample reservoir, and comparison of these spectra to the 
original un-filtered spectra, large amounts of albumin were still present within the 
samples. The spectra obtained from the fluid remaining in the sample reservoir were 
very similar in appearance to the non-filtered whole serum spectra, almost displaying 
identical FTIR spectroscopy signals in most cases.  Spectra obtained from the filtrate 
fluids displayed very weak signals, indicating albumin was not effectively removed from 
the plasma samples.  
3.5. Discussion 
Within the limited sample size used, this study was unable to develop an infrared 
spectroscopic assay as an accurate technique for the measurement of Ig isotypes in 
equine plasma. It is possible that the Ig isotype concentrations evaluated were too low, 
and cover such a narrow range of values, that their identification via IR spectroscopy is 
more difficult than for previously published techniques for total equine plasma and 
serum IgG (5, 25).  
For this study, IgGb showed the strongest level of agreement between FTIR and 
ELISA results, with correlation coefficients of 0.89 and 0.71 for the training and 
prediction sets, respectively. This is likely due to the fact that IgGb is the predominant 
IgG subclass found in equine serum, accounting for >60% of the total serum IgG 
concentration, which itself is the most abundant isotype in body fluids, typically having 
concentration values 10 to 100 times greater than IgA or IgM (13, 19-21, 30). As a result, 
IgGb is the predominant Ig constituent in equine plasma and this fact, combined with 
the results of this study, support the theory that it is less difficult to develop a successful 
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FTIR quantitation algorithm when the Ig to be measured is in higher concentrations. 
Further work is required to identify methods which may improve algorithm 
development for the measurement of lower-concentration Ig’s in equine plasma.  
A potential reason for the disagreement noted in this study between FTIR and 
ELISA generated results may in part be due to other confounding plasma constituents 
which overshadow the lower-concentration Ig’s in equine plasma. Plasma is a complex 
biological fluid consisting of numerous proteins, peptides, glycosaminoglycans, and 
exogenous substances (4, 31). Proteins normally found in equine plasma include 
albumin, Ig’s, fibrinogen, α1 -antitrypsin, transferrin and many others (31).  Within this 
large repertoire of equine plasma proteins, albumin and Ig’s (predominately IgG) are 
often the most abundant proteins measured (31). In particular, plasma albumin is 
considered the most abundant protein of the mammalian circulatory system and has a 
molecular weight ranging between 65-68kDa (32, 33).  
Due to its abundance, it was hypothesized that the absorption bands produced 
by albumin within a plasma sample may overlap the IR bands of interest (such as those 
for the Ig isotypes). For this reason, a trial using Nanosep® 100K filter devices was 
performed in an attempt to remove albumin from the equine plasma samples and allow 
other constituents (such as the immunoglobulin isotypes and subclasses) with smaller 
concentrations to feature more prominently in the resulting IR spectra (31).  
Unfortunately, in this study the Nanosep® filtration devices failed to effectively remove 
enough albumin from our equine plasma samples to obtain meaningful results. 
Consequently, a potential area for further research may be to identify different methods 
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of albumin removal in an attempt to enhance the detection of equine Ig isotypes on 
resulting IR spectra.   
Over the past two decades, increasing interest in the proteome of human serum 
and plasma has resulted in a large amount of research dedicated solely to the specific 
removal of albumin from these biofluids, in order to discover and/or detect proteins 
existing in lower concentrations (34-36). Authors of these studies believe that many of 
these lower-abundance proteins may provide useful clinical data on the physiological or 
clinical status of patients or serve as biomarkers of various disease conditions (34, 35). 
Several techniques have been proposed for the removal of albumin from human plasma 
and serum samples (34, 37). Similar to our study, methods attempting to remove 
plasma albumin by molecular weight separation via centrifugal filtration have proven 
unsuccessful in human research (37). Other methods relying on the affinity of albumin 
for certain blue textile dyes have proven effective at removing albumin from serum, yet 
these methods lack specificity as various other serum proteins also bind to the dye-
based resins (34-36). Chen et al. described a method of precipitating albumin out of 
human serum using a trichloroacetic acid/acetone combination (35). With this method, 
they were able to remove 60% of albumin from their serum samples, with Ig’s becoming 
the predominant proteins found in the resulting precipitate (35). In another study 
investigating the use of antibodies against human serum albumin, the authors were able 
to develop an immunoaffinity resin capable of removing albumin from serum (34). This 
method proved more efficient and specific than dye-based methods of albumin 
removal, however, the quantity of antibody required proved both problematic and 
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costly (34). Finally, a depletion of albumin component (DOC) protocol was developed 
which utilized a chemical based extraction method for the removal of albumin from 
human serum (36). This DOC protocol was able to effectively and specifically remove 
albumin from serum samples, thereby facilitating the detection and identification of 
many less abundant proteins within the samples (36). These studies in human literature 
provide useful insight into possible future directions for albumin depletion in equine 
serum. 
Another potential limitation in this study was the use of ELISA assays as the 
reference standard to which to compare our FTIR algorithm-derived Ig results. In 
particular, the ELISA assays used for this study had considerable potential for human 
error with requirements for both high plasma and detection antibody dilutions. For 
example, with the IgGb assay, a plasma dilution of 1:200,000 and a detection antibody 
dilution of 1:65,000 were required. This resulted in only a few microliters of plasma or 
detection antibody being diluted in a large volume of diluent, thus allowing for possible 
errors in calculating, measuring or performing the dilutions. Any such error could then 
have the potential to significantly alter or skew the ELISA results in this study.  
During the study, another technical difficulty encountered with the ELISA assays 
was the inability to consistently have the OD value for the highest standard of a 
particular kit to fall within the manufacturer’s required range of 1.8 – 2-2. As an 
example, when initially using the IgGb assay, the OD value for the highest standard was 
> 2.2 on the first day, then fell within or below the range the next day, despite using the 
same procedure, materials and detection antibody dilution. This problem also occurred 
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with the IgGa and IgM and ELISA assays. In order to deal with this issue, multiple trials 
were performed to determine the most appropriate detection antibody dilution for each 
of the Ig isotype ELISA assays. The dilution of detection antibody which best allowed for 
the highest standard of that specific assay kit to fall within the range of 1.8 – 2-2 was 
chosen. Once this was determined, all 100 serum samples were run with that particular 
Ig ELISA assay kit by a single individual at the same time using the pre-determined 
detection antibody dilution. By doing this, it also allowed the same batch of coating 
antibody, wash solution, diluent and TMB substrate solution to be used for all 100 
samples run, thereby increasing the consistency among the 100 sample results for each 
Ig isotype or subclass.  
Due to the difficulties experienced with the ELISA assays in this project, it is 
reasonable to assume that other laboratories may have experienced similar problems. If 
so, what was perceived as significant differences between the results of this study and 
those previously mentioned, may be more attributable to interlab variation when 
running the ELISA assays. Not only were significant differences noted between our ELISA 
Ig concentration results and those found in the previously published studies, but one of 
the published papers also identified poor levels of agreement among some of the results 
found in current literature (13, 19-21). These findings indicate that there are currently 
no consistent published data regarding the normal concentration ranges of Ig isotypes in 
equine plasma using the ELISA assay. Further work, with larger data sets, is needed to 
establish universal reference ranges for Ig isotypes and subclasses in adult and foal 
plasma.   
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The mean IgG concentration determined by RID assay was found to be 
statistically different than the ELISA determined total IgG concentrations for the 100 
equine plasma samples. In horses, IgGb is the predominant equine IgG subclass 
(constituting > 60%), followed by IgG(T), then IgGa and finally IgGc (which normally 
accounts for < 1% of the total IgG concentration) (30). In this study, the ELISA total IgG 
concentrations were obtained by summing IgGa, IgGb and IgG(T), which left IgGc as the 
only IgG subclass not accounted for. When comparing the data, it is evident that the 
ELISA total IgG concentrations were underestimated as 74% were more than 10 g/L 
lower than their corresponding RID values. Based on these results, the absence of IgGc 
from our ELISA total IgG concentrations cannot account for such a sizable difference as 
to do so would require the plasma IgGc concentrations to be higher than the IgGb 
values (which is highly improbable).  Therefore, it is logical to assume that the ELISA 
determined IgG subclass concentrations, IgGb in particular, in this study were 
underestimated by the ELISA assays.  
Only two of the previous studies reviewed attempted to quantify IgGa, IgGb and 
IgG(T) in equine serum (19, 21). These studies each used an ELISA assay for IgG subclass 
quantification and their IgGb results displayed no statistical difference from one another 
(21). In contrast, our mean ELISA IgGb concentration (9.21 g/L) was significantly 
different than the mean IgGb concentrations (19.60 g/L for Sheoran et al. and 16.87 g/L 
for Holznagel et al.) found in each the aforementioned studies (19, 21). These findings 
further highlight the likelihood that the ELISA assay used in this study underestimated 
the equine plasma IgGb concentrations which in turn led to the low total IgG values 
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calculated. Since completion of this project, the commercial IgGb ELISA assay used for 
this study has been discontinued by the manufacturers; making repeat testing of the 
samples with the ELISA impossible.  
An additional source for potential error within this study could relate to the age 
and prior usage of the equine plasma samples themselves. The samples were over 5 
years old at their time of use in this study and consequently had been exposed to 
multiple freeze-thaw cycles. This may have resulted in some degree of degradation of 
constituents, despite reasonable precautions being taken with respect to sample 
refrigeration. Although it is possible the protein composition of the samples may have 
changed with time, current literature indicates this is an unlikely cause of the 
discrepancies noted between FTIR and ELISA generated Ig concentrations in this study 
(38).  
A study evaluating the stability of select proteins in human serum concluded that 
long term storage (>25 years at -20oC) of serum did not significantly alter the 
concentrations of certain proteins within that sample (38). In particular, this study 
evaluated serum albumin, IgE and IgG and concluded that it is possible to obtain reliable 
concentration results for these proteins, even in samples which have been undergone 
long term storage (38). Another study was able to demonstrate the long term stability of 
IgE within human serum samples stored long term (32-37 years) at -20oC (39). The 
authors were able to conclude that it is possible to reliably measure IgE concentrations 
in serum samples which have been stored long term (>30 years at -20oC) (39). While 
these studies investigated the effects of long term storage on human serum, they still 
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provide circumstantial evidence that the Ig concentrations in our equine plasma 
samples should be relatively stable and reliable, despite their longer storage time at -
80oC.  
Studies in both human and veterinary literature have investigated the effects of 
storage temperature and freeze-thaw cycles on different biochemical constituents of 
both serum and plasma samples (40-43). Human, canine and rat serum has been 
reported to be most stable, and therefore having the fewest changes in analyte levels, 
when stored long term at a temperature of -70oC (40). As well, a study assessing the 
effects of various freeze-thaw cycles on 13 canine plasma components (including total 
protein) found no significant differences between the original component 
concentrations and those concentrations calculated after one, two and three freeze-
thaw cycles (42). These studies lend additional evidence that the storage time, 
temperature and freeze-thaw cycles of our equine plasma samples, while still potentially 
having mild changes in the protein concentrations within those samples, are not likely 
important factors in this study.  
In conclusion, significant discrepancies were noted between the ELISA Ig isotype 
concentrations found in this study and those reported in the literature. It is unknown 
whether these differences are the result of interlab variability between testing methods 
or true differences among study groups. Regardless, further work is required to 
establish normal reference ranges for Ig isotypes and subclasses in adult plasma using 
an alternative analytical method. Additionally, further research is needed to identify the 
potential uses of Fourier-transform infrared spectroscopy in the quantification of Ig 
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isotypes in equine plasma. Studies using albumin-depleted plasma may be useful to 
better identify Ig isotypes within resulting IR spectra. If successful, these studies may 
provide valuable data to further enhance and refine the calibration model and algorithm 
development for the measurement of Ig isotypes in equine plasma.  
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3.6. Footnotes 
a HTS-XT autosampler, Bruker Optics®, Milton, ON, Canada 
b Tensor 37, Bruker Optics®, Milton, ON, Canada 
c OPUS® ver. 6.5, Bruker Optics®, Milton, ON, Canada 
d  Microplate reader, Tecan Group Ltd., Markham, ON, Canada 
e Spectra Max Plus 384, Molecular Devices, Sunnyvale, CA, USA 
f SoftMax Pro 5 software, Molecular Devices, Sunnyvale, CA, USA 
g GRAMS software ver. 7.02, Thermo Fisher Scientific Inc, Waltham, MA, USA 
h MATLAB MathWorks R2011b, Natick, MA, USA 
i Minitab 16.0, Minitab Inc.®, State College, PA, USA 
j Cary 630 FTIR spectrometer, Agilant Technologies Canada Inc., Mississauga, ON 
k MicroLab FTIR software, Agilant Technologies Canada Inc., Mississauga, ON 
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Table 3.1. Comparison of the mean (±SD) serum immunoglobulin concentrations (g/L) of 
IgGa, IgGb, IgG(T), IgM and IgA found in this study to the studies by Sheoran et al., de 
Camargo et al., McFarlane et al. and Holznagel et al. (13, 19-21). An (*) denotes the Ig 
concentration results which differed significantly from the results of this study.  
 
 Burns 
(n=100) 
Sheoran 
(n=27) 
deCamargo 
(n=44 for 
IgG(T), n=19 
for IgA, n=47 
for IgM) 
McFarlane 
(n=30) 
Holznagel 
(n=5) 
ELISA assays ELISA assays RID assays RID assays ELISA assays 
Mean SD Mean SD Mean SD Mean SD Mean SD 
IgGa 2.718 0.767 3.4 2.0 --- --- --- --- 3.68* 0.62 
IgGb 9.207 2.465 19.6* 6.5 --- --- --- --- 16.87* 1.96 
IgG(T) 4.964 2.350 4.0 2.5 4.19 2.20 6.89* 1.85 8.36* 1.79 
IgA 1.013 0.760 0.4* 0.3 1.96* 0.73 2.99* 0.46 0.58* 0.21 
IgM 0.789 0.313 --- --- 0.70 0.30 1.91* 0.73 --- --- 
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Figure 3.1 Scatter plots comparing the IgGa concentrations in the training set (A) 
(Pearson correlation coefficient = 0.55) and test set (B) (Pearson correlation coefficient = 
0.46) obtained from ELISA and FTIR methods. If ELISA and FTIR give comparable results, 
the data points should distribute closely around the reference line of 45o.  
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Figure 3.2 Scatter plots comparing the IgGb concentrations in the training set (A) 
(Pearson correlation coefficient = 0.89) and test set (B) (Pearson correlation coefficient = 
0.71) obtained from ELISA and FTIR methods. If ELISA and FTIR give comparable results, 
the data points should distribute closely around the reference line of 45o. 
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Figure 3.3 Scatter plots comparing the IgG(T) concentrations in the training set (A) 
(Pearson correlation coefficient = 0.88) and test set (B) (Pearson correlation coefficient = 
0.24) obtained from ELISA and FTIR methods. If ELISA and FTIR give comparable results, 
the data points should distribute closely around the reference line of 45o. 
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Figure 3.4 Scatter plots comparing the IgA concentrations in the training set (A) 
(Pearson correlation coefficient = 0.62) and test set (B) (Pearson correlation coefficient = 
0.09) obtained from ELISA and FTIR methods. If ELISA and FTIR give comparable results, 
the data points should distribute closely around the reference line of 45o. 
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Figure 3.5 Scatter plots comparing the IgM concentrations in the training set (A) 
(Pearson correlation coefficient = 0.66) and test set (B) (Pearson correlation coefficient = 
0.27) obtained from ELISA and FTIR methods. If ELISA and FTIR give comparable results, 
the data points should distribute closely around the reference line of 45o. 
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CHAPTER 4 
GENERAL DISCUSSION 
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4.1. Summary of findings 
The primary objective of this project was to investigate the use of Fourier-
transform infrared (FTIR) spectroscopy for the quantification of specific immunoglobulin 
(Ig) isotypes and subclasses in equine and camelid serum. In the first chapter of this 
thesis, a detailed review of relevant current literature identified important factors which 
provided evidence for pursuing this research. First and foremost, chapter 1 highlighted 
the need for improved testing methods to aid in the diagnosis of immunodeficiency 
disorders in camelid and equine species. More specifically, it emphasized the demand 
for an accurate, rapid and economical assay to quantify immunoglobulin G (IgG) in 
camelid serum. It also outlined the current lack of specific and sensitive testing options 
available for the measurement of Ig isotypes (other than IgG) or IgG subclasses in equine 
serum.  
The first chapter also introduced the background and methodologies relating to 
infrared spectroscopy, as well as its current applications in both human and veterinary 
medicine. Considerable research has shown FTIR-based analytical methods to have 
excellent accuracy for the screening, diagnosis or classification of various diseases in 
both human and animal species (1-4). However, despite this success, limited research to 
date has focused on the use of FTIR spectroscopy for the measurement of Ig 
concentrations in human or animal serum (5, 6). Prior to this study, only two 
publications were found detailing the use of infrared spectroscopy for the quantification 
of serum or plasma Ig’s in an animal species ( both of which were performed at the 
Atlantic Veterinary College [AVC]) (5, 7). As a result, this present study is the first to 
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report the use of FTIR spectroscopy for the measurement of IgG in camelid serum. This 
study also examined the potential of FTIR spectroscopy for the measurement of equine 
Ig isotypes (other than IgG) and IgG subclasses, building on of previous research at the 
AVC where total IgG concentrations were effectively measured in equine serum (5). 
The second chapter of this thesis specifically examined the ability of FTIR 
spectroscopy to measure alpaca serum IgG concentrations. To do this, serum from 175 
privately-owned, healthy alpacas was analysed by radial immunodiffusion (RID) assay 
and FTIR spectroscopy. An algorithm for an infrared based assay was built using partial 
least squares regression to convert the spectroscopic data into quantitative values 
which were then compared with their RID-derived counterparts. Scatter plots and 
Pearson correlation coefficients indicated that the FTIR predicted IgG concentrations 
had good to excellent correlation with RID determined IgG concentrations. As a result, 
this study confirmed that FTIR spectroscopy, in combination with chemometrics, is a 
promising technique for the measurement of IgG concentrations in camelid serum. This 
data is believed to be the first published work outlining the use of FTIR spectroscopy for 
the quantification of IgG levels in camelid serum.      
One limitation identified in chapter two of this thesis was the relatively small 
number of camelid serum samples with low IgG concentrations in the data set. The 
samples collected for this study were convenience samples obtained during routine 
herd health visits to alpaca farms in Ontario and New Brunswick, Canada and Adelaide, 
Australia. Consequently, the majority of samples were from adult alpacas with IgG 
concentrations in the normal range (>1000 mg/dl) with only 21 of the 175 samples used 
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in this study having low serum IgG concentrations (<1000 mg/dl) based on RID. This may 
affect the algorithm’s accuracy in predicting IgG values at lower concentrations (as 
algorithm development was weighted toward higher IgG concentrations) for FTIR. 
The focus for the third chapter of this thesis was to develop FTIR based assays 
for the measurement IgGa, IgGb, IgG(T), IgA, and IgM in equine plasma using enzyme 
linked immunosorbent assays (ELISA) as the “gold standard” reference test. A second 
objective was to compare the ELISA IgGa, IgGb, IgG(T), IgA, and IgM concentrations 
measured in this study to the results of previous studies found in the literature. 
Methods similar to those used in chapter two were employed to build a calibration 
model and algorithm which would covert the FTIR spectra obtained from 100 adult 
equine plasma samples into quantitative values. These results were then compared to 
IgGa, IgGb, IgG(T), IgA, and IgM concentrations calculated via ELISA assays. With the 
exception of IgGb, the FTIR-predicted Ig isotypes exhibited a poor correlation with their 
corresponding ELISA-determined concentrations. It was speculated that this may in part 
be due to the relatively low plasma concentrations of these isotypes and subclasses 
relative to total IgG as well as interference from other confounding constituents, such as 
albumin, which are normally found in high plasma concentrations (8). Absorption bands 
produced by these confounders may overlap the bands of interest (such as the Ig 
isotypes or subclasses) on the infrared (IR) spectra, thereby not allowing plasma 
components with smaller concentrations to be easily identified and measured. These 
findings indicate that further research is needed to identify preprocessing methods for 
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Ig isotype/subclass concentration, if FTIR spectroscopy is to be of practical use for the 
quantification of Ig isotypes or subclasses in equine plasma. 
Limited studies to date have attempted to quantify Ig isotypes and IgG 
subclasses in equine plasma (9-12). Of those studies which were found in the current 
literature, significant discrepancies were noted between reported concentrations (12). 
As a result, there is currently no unifying published data regarding the normal 
concentration ranges of Ig isotypes or IgG subclasses in equine plasma. Therefore, part 
of the focus for the third chapter of this thesis was to compare the ELISA IgGa, IgGb, 
IgG(T), IgA, and IgM concentrations measured in this study to the results of previous 
research. Significant discrepancies were noted between the concentrations found in this 
study and at least one or more of the Ig isotypes or IgG subclasses measured in each of 
the previous studies.  
Perhaps the most important issue identified in chapter 3 was the significant 
difference noted between the mean RID IgG concentrations and the ELISA determined 
total IgG concentrations for the 100 equine plasma samples. For the past number of 
years, RID assays have been considered the gold standard reference method for the 
quantitation of serum or plasma IgG (5). As a result, when comparing the ELISA total IgG 
concentrations to their corresponding “gold standard” RID values, it becomes evident 
that the ELISA assays inaccurately measured the IgG subclasses by underestimating their 
true concentrations.  
4.2. Future directions 
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The present study provided a basis for the potential use of FTIR spectroscopy in 
camelid IgG measurements. However, as previously mentioned, a significant limitation 
was the small number of serum samples with low IgG concentrations. An important next 
step would be to obtain a data set with a  larger proportion of cria (particularly those 
<24 hours of age) serum samples. By doing so, it should increase the number of samples 
with IgG concentrations <1000 mg/dl. This would allow further modification of the 
quantitative algorithm which may improve its performance for the measurement of 
serum samples with lower IgG concentrations. 
This study was unable to demonstrate that the concentrations of IgGa, IgGb, 
IgG(T), IgA, and IgM in equine plasma can be measured by FTIR spectroscopy. It appears 
more difficult to build an effective algorithm for the FTIR assays when the analyte to be 
measured is in low concentrations in the blood (due to interference from other higher 
concentration constituents). More specifically, it is suspected that the absorption bands 
produced by albumin within the plasma samples of this study were overlapping the Ig 
bands of interest on the infrared spectra, therefore causing difficulties in developing an 
effective algorithm for the IgGa, IgGb, IgG(T), IgA, and IgM.  Further research 
investigating the preprocessing of plasma samples to remove albumin is warranted.  
Attempts to remove plasma albumin by molecular weight separation via 
centrifugal filtration were unsuccessful in this project. However, various studies in 
human literature have outlined other promising methods for albumin depletion of 
serum samples (13-15). Based on this, a logical next step for future research would be to 
explore some of these methods and assess their feasibility in albumin depletion of 
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equine plasma samples. Certain techniques, such as affinity-based methods or 
immunoaffinity resins, would likely prove inadequate due to their lack of specificity, 
increased cost or low commercial availability (13-15). However, other methods such as 
the depletion of albumin component (DOC) protocol outlined by Colantonio et al., may 
have potential success with equine plasma samples (14). With this chemical based 
extraction method, which utilizes compounds routinely found in most laboratories, the 
authors’ were able to successfully remove large volumes of serum albumin, while still 
maintaining the Ig’s within the sample (14). The apparent success, ease of use and low 
cost of this method in human studies make it a promising method to explore with 
equine plasma samples (14).    
Following the success of FTIR spectroscopy for the measurement of IgG 
concentrations in camelid and equine serum, an additional direction for future research 
should explore its potential to quantify IgG levels in colostral samples of these species. 
Previous research has demonstrated the ability of infrared spectroscopy in the analysis 
of various bovine milk sample components, therefore it would be logical to assume that 
similar work can be done with equine and camelid colostrum (16-18). If successful, this 
could provide a rapid, inexpensive tool to identify foals and crias at risk for failure of 
transfer of passive immunity (FTPI) (due to inadequate colostrum IgG concentrations in 
the dam).  In doing so, early, proper medical intervention could be provided to minimize 
the risk of FTPI in the neonate.   
A final subject for future research would be to use FTIR spectroscopy for the 
investigation of serum IgG concentrations in horses of different age groups, breeds and 
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under different training conditions. This research would also be beneficial for IgA and 
IgM, if methods to accurately quantify these isotypes using FTIR spectroscopy become 
established. A study such as this would allow researchers to identify whether different 
physiological conditions (i.e. age, breed, physical activity level) influence the normal 
serum Ig isotype concentrations in these animals. As many immunodeficiencies in 
horses rely upon the measurement of certain Ig levels for diagnosis, establishing normal 
reference ranges for different equine populations would be an important step to ensure 
proper diagnoses for these diseases in horses.  
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APPENDIX A. ENZYME-LINKED IMMUNOSORBENT ASSAYS FOR IgGa, IgGb, IgG(T), IgA 
AND IgM  
Section 1. STANDARD DILUTIONS 
Horse IgGa ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX)  
To make standard concentration values of 200 ng/ml, 100 ng/ml, 50 ng/ml, 25 ng/ml, 
12.5ng/ml, 6.25 ng/ml, 3.12 ng/ml and 0 ng/ml: 
1. Dilute 5 µl of horse reference serum (1.8 mg/ml IgGa) in 9 ml of diluent to make 
an initial 1000 ng/ml dilution. 
2. Dilute 500 µl of the initial (1000 ng/ml) dilution in 2 ml of diluent to make a 200 
mg/ml dilution. 
3. Serially dilute the 200 ng/ml dilution 1:1 6 times until a dilution of 3.12 ng/ml is 
reached. 
4. Use 500 µl diluent as the zero standard value. 
Horse IgGb ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX)  
To make standard concentration values of 200 ng/ml, 100 ng/ml, 50 ng/ml, 25 ng/ml, 
12.5ng/ml, 6.25 ng/ml, 3.12 ng/ml and 0 ng/ml: 
1. Dilute 5 µl of horse reference serum (9.0 mg/ml IgGb) in 4.5 ml of diluent to 
make an initial 10 000 ng/ml dilution. 
2. Dilute 100 µl of the initial (10 000 ng/ml) dilution in 4.9 ml of diluent to make a 
200 mg/ml dilution. 
3. Serially dilute the 200 ng/ml dilution 1:1 6 times until a dilution of 3.12 ng/ml is 
reached. 
4. Use 500 µl diluent as the zero standard value. 
Horse IgG(T) ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX)  
To make standard concentration values of 1,000 ng/ml, 500 ng/ml, 250 ng/ml, 125 
ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml and 0 ng/ml: 
1. Dilute 5 µl of horse reference serum (3.8 mg/ml IgG(T)) in 19.0 ml of diluent to 
make an initial 1 000 ng/ml dilution. 
2. Serially dilute the 1000 ng/ml dilution 1:1 6 times until a dilution of 15.6 ng/ml is 
reached. 
3. Use 500 µl diluent as the zero standard value. 
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Horse IgA ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX)  
To make standard concentration values of 1,000 ng/ml, 500 ng/ml, 250 ng/ml, 125 
ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml and 0 ng/ml: 
1. Dilute 5 µl of horse reference serum (1.5 mg/ml IgA) in 7.5 ml of diluent to make 
an initial 1 000 ng/ml dilution. 
2. Serially dilute the 1000 ng/ml dilution 1:1 6 times until a dilution of 15.6 ng/ml is 
reached. 
3. Use 500 µl diluent as the zero standard value. 
Horse IgM ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX)  
To make standard concentration values of 1,000 ng/ml, 500 ng/ml, 250 ng/ml, 125 
ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml and 0 ng/ml: 
1. Dilute 5 µl of horse reference serum (1.0 mg/ml IgM) in 5.0 ml of diluent to make 
an initial 1 000 ng/ml dilution. 
2. Serially dilute the 1000 ng/ml dilution 1:1 6 times until a dilution of 15.6 ng/ml is 
reached. 
3. Use 500 µl diluent as the zero standard value. 
 
Section 2. RECOMMENDED STARTING DETECTION ANTIBODY DILUTIONS 
Horse IgGa ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
To make the manufacturer’s recommended 1:35 000 detection antibody dilution: 
1. Dilute 2µl of the appropriate HRP-conjugated detection antibody in 2 ml of 
diluent to make an initial dilution of 1:1,000. 
2. Dilute 0.1 ml of the initial (1:1000) dilution in 3.4 ml of diluent (a 1:35 dilution) to 
make a final dilution of 1:35 000. 
Horse IgGb ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
To make the manufacturer’s recommended 1:60 000 detection antibody dilution: 
1. Dilute 2µl of the appropriate HRP-conjugated detection antibody in 2 ml of 
diluent to make an initial dilution of 1:1,000. 
2. Dilute 0.1 ml of the initial (1:1000) dilution in 5.9 ml of diluent (a 1:60 dilution) to 
make a final dilution of 1:60 000. 
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Horse IgG(T) ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
To make the manufacturer’s recommended 1:75 000 detection antibody dilution: 
1. Dilute 2µl of the appropriate HRP-conjugated detection antibody in 2 ml of 
diluent to make an initial dilution of 1:1,000. 
2. Dilute 0.1 ml of the initial (1:1000) dilution in 7.4 ml of diluent (a 1:75 dilution)  
to make a final dilution of 1:75 000. 
Horse IgA ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
To make the manufacturer’s recommended 1:100 000 detection antibody dilution: 
1. Dilute 2µl of the appropriate HRP-conjugated detection antibody in 2 ml of 
diluent to make an initial dilution of 1:1,000. 
2. Dilute 0.1 ml of the initial (1:1000) dilution in 9.9 ml of diluent (a 1:100 dilution) 
to make a final dilution of 1:100 000. 
Horse IgM ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
To make the manufacturer’s recommended 1:35 000 detection antibody dilution: 
1. Dilute 2µl of the appropriate HRP-conjugated detection antibody in 2 ml of 
diluent to make an initial dilution of 1:1,000. 
2. Dilute 0.1 ml of the initial (1:1000) dilution in 3.4 ml of diluent (a 1:35 dilution) to 
make a final dilution of 1:35 000. 
 
Section 3. DETECTION ANTIBODY DILUTION TRIALS 
Horse IgGa ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
The recommended detection antibody starting dilution of 1:35 000 made the optical 
density (OD) value for the highest standard fall above the required range of 1.8-2.2. 
According to manufacturer’s instructions, a higher dilution factor was required to lower 
the OD value. To determine the optimal detection antibody concentration for the IgGa 
ELISA kit, a trial was conducted:  
1. 4 dilutions were made using the HRP conjugated horse IgGa detection antibody: 
1:35,000, 1:40,000, 1:45,000 and 1:50 000. 
2. These dilutions were each added to duplicate wells containing the three highest 
standards (200 ng/ml, 100 ng/ml, 50 ng/ml) of the IgGa ELISA kit. 
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3. The ELISAs were otherwise performed according to manufacturer’s instructions. 
4. The dilution which best allowed the highest standard to fall within the desired 
1.8-2.2 range was chosen for this study.  
Horse IgGb ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
The recommended detection antibody starting dilution of 1:60 000 made the optical 
density (OD) value for the highest standard fall above the required range of 1.8-2.2. 
According to manufacturer’s instructions, a higher dilution factor was required to lower 
the OD value. To determine the optimal detection antibody concentration for the IgGb 
ELISA kit, a trial was conducted:  
1. 4 dilutions were made using the HRP conjugated horse IgGb detection antibody: 
1:60,000, 1:70,000, 1:75,000 and 1:80,000 
2. These dilutions were each added to duplicate wells containing the three highest 
standards (200 ng/ml, 100 ng/ml, 50 ng/ml) of the IgGb ELISA kit. 
3. The ELISAs were otherwise performed according to manufacturer’s instructions. 
4. The dilution which best allowed the highest standard to fall within the desired 
1.8-2.2 range was chosen for this study.  
Horse IgM ELISA quantitation set (Bethyl Laboratories Inc.; Montgomery, TX) 
The recommended detection antibody starting dilution of 1:35 000 made the optical 
density (OD) value for the highest standard fall above the required range of 1.8-2.2. 
According to manufacturer’s instructions, a higher dilution factor was required to lower 
the OD value. To determine the optimal detection antibody concentration for the IgM 
ELISA kit, a trial was conducted:  
1. 4 dilutions were made using the HRP conjugated horse IgM detection antibody: 
1:40,000, 1:45,000, 1:50 000 and 1:55 000. 
2. These dilutions were each added to duplicate wells containing the three highest 
standards (1000 ng/ml, 500 ng/ml, 250 ng/ml) of the IgM ELISA kit. 
3. The ELISAs were otherwise performed according to manufacturer’s instructions. 
4. The dilution which best allowed the highest standard to fall within the desired 
1.8-2.2 range was chosen for this study. 
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APPENDIX B.  EXPLORATORY TRIALS INTO THE USE OF NANOSEP® CENTRIFUGAL 
FILTRATIONS DEVISES FOR THE REMOVAL OF ALBUMIN FROM EQUINE 
PLSAMA 
 
Section 1. FILTRATION DEVICE SIZE SELECTION  
Nanosep® centrifugal filter devices (Pall Life Sciences; Ann Arbor, MI) with 
100kDa omega membrane filters were chosen to allow the passage of albumin 
(molecular weight <100 KDa) through the filter into the filtrate receiver while 
concurrently trapping immunoglobulins (molecular weight >100 KDa) on top of the 
membrane within the sample reservoir. 
 
Section 2. FILTRATION TRIALS  
2.1 Initial filtration trial  
 2 equine plasma samples were thawed at room temperature 
 0.4ml of each sample was pipetted into the sample reservoir of a 
filtration device  
 The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g for 20 minutes (in 5 minute increments) 
 
This attempt to filter plasma with the filtration devices proved unsuccessful as a large 
portion (> 3/4) of the samples remained unfiltered within the sample reservoir, despite 
142 
 
adequate centrifugation. Potentials reasons for this could include a problem with the 
filtration membrane itself, too high of a starting plasma volume or increased viscosity of 
the samples to be measured thus not allowing proper filtration through the membrane. 
Subsequently, results from this initial trial were discarded and additional trials were 
performed to identify whether one of these problems could account for the poor 
filtration of our equine plasma samples with the Nanosep® filtration devices.  
 
2.2 Filtration trial to test the permeability of the omega membrane within 
the Nanosep® 100K centrifugal filter devices 
 0.5ml of sterile saline was pipetted into the sample reservoirs of two 
filtration devices 
 The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g for 5 minutes 
 
When both of the 0.5ml saline samples were able to pass completely through the 
membrane and into the filtrate receiver after 5 minutes of centrifugation, it was 
concluded that the filter membrane was functioning properly.  
 
2.3 Filtration trial using 1:1 diluted plasma 
 2 equine plasma samples were thawed at room temperature 
 The plasma samples were diluted 1:1 with sterile saline (0.25ml of plasma 
+ 0.25ml of saline) 
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 The diluted samples were pipetted into the sample reservoirs of a 
filtration device 
 The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g for 20 minutes (in 5 minute increments) 
 Following centrifugation, the original serum samples, the remaining fluids 
in the sample reservoirs and the fluids collected in the filtrate receivers of 
the filtration device were each separately analysed using an FTIR 
spectrometer: 
o 4l aliquots were evenly distributed onto the diamond crystal 
embedded in the steel sampling surface of the spectrometer 
o Samples were dried for four minutes using the ‘cool’ setting of a 
hairdryer which was positioned six inches from the sampling 
surface of the IR machine 
o Absorbance spectra in the IR range of 400-4000 cm-1 were 
recorded (resolution 4 cm-1) for each sample using the FTIR 
analyzer and its associated software 
o Five sample replicates were analyzed for each of the sample 
sections 
o Each of the original two (unfiltered) plasma samples were diluted 
1:1 with sterile saline (40µl serum + 40µl saline) prior to analysis 
with the FTIR spectrometer (as outlined above) 
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For each sample, visual examination and comparison of the residual in the sample 
reservoir to the original un-filtered spectra indicate a large amount of albumin was still 
present within the sample. When the two spectra were displayed on the same graph, 
they overlapped extensively, exhibiting a very similar appearance.  Spectra obtained 
from the filtrate fluid displayed a weak signal, indicating that albumin had not been 
effectively removed from the sample. 
 
2.4 Filtration trial using a decreased starting plasma volume  
 1 equine plasma sample was thawed at room temperature 
 0.1ml of sample was pipetted into the sample reservoir of a filtration 
device  
 The filtration device was placed in a fixed-angle centrifuge rotor and spun 
at 14,000g for 10 minutes (in 5 minute increments) 
 Following centrifugation, both the original plasma sample, the remaining 
fluid in the sample reservoir and the fluid collected in the filtrate receiver 
of the filtration device were each separately analysed using an FTIR 
spectrometer (as detailed above in subsection 2.3) 
 
Visual examination and comparison of the residual in the sample reservoir to the 
original un-filtered spectra indicate a large amount of albumin was still present within 
the sample. When the two spectra were displayed on the same graph, they overlapped 
extensively, exhibiting a very similar appearance.  Spectra obtained from the filtrate 
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fluid displayed a weak signal, indicating that albumin had not been effectively removed 
from the sample. 
 
 
2.5 Filtration trial using an increased plasma dilution 
 1 equine plasma sample was thawed at room temperature 
 The plasma sample was diluted 1:5 with sterile saline (0.1ml of plasma + 
0.4ml of saline) 
 The diluted sample was pipetted into the sample reservoir of a filtration 
device  
 The filtration device was placed in a fixed-angle centrifuge rotor and spun 
at 14,000g for 20 minutes (in 5 minute increments) 
 Following centrifugation, both the original plasma sample, the remaining 
fluid in the sample reservoir and the fluid collected in the filtrate receiver 
of the filtration device were each separately analysed using an FTIR 
spectrometer (as detailed above in subsection 2.3) 
 
Visual examination and comparison of the residual in the sample reservoir to the 
original un-filtered spectra indicate a large amount of albumin was still present within 
the sample. When the two spectra were displayed on the same graph, they overlapped 
extensively, exhibiting a very similar appearance.  Spectra obtained from the filtrate 
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fluid displayed a weak signal, indicating that albumin had not been effectively removed 
from the sample. 
 
2.6 Additional filtration trial using increased plasma dilutions 
 3 equine plasma sample were thawed at room temperature 
 Each plasma sample was diluted 1:10 (50µl plasma + 450µl sterile saline), 
1:20 (25µl plasma + 475µl sterile saline), 1:50 (10µl plasma + 490µl sterile 
saline) and 1:100 (5µl plasma + 495µl sterile saline)  
 The diluted samples were each pipetted into the sample reservoir of a 
filtration device  
 The filtration devices was placed in a fixed-angle centrifuge rotor and 
spun at 14,000g in 5 minute increments - the 1:50 and 1:100 plasma 
dilutions were centrifuged for a total of 10 minutes and the 1:10 and 1:20 
plasma dilutions were centrifuged for a total of 15 minutes 
 Following centrifugation, the remaining fluids in the sample reservoirs 
and the fluid collected in the filtrate receivers of the filtration devices 
were each analysed using an FTIR spectrometer (as detailed above in 
subsection 2.3) 
 
For each sample, visual examination and comparison of the residual fluid in the sample 
reservoir to the original un-filtered spectra indicated a large amount of albumin was still 
present within the sample. When the two spectra were displayed on the same graph, 
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substantial overlap was still present and they exhibited a similar appearance, yet, mild 
changes were apparent indicating some compounds have been removed from the 
filtered spectra.  However, spectra obtained from the filtrate fluid still displayed a weak 
signal, indicating that albumin had not been effectively removed from the sample. 
 
2.7 Filtration trial using washed omega membranes 
Further experimentation was conducted to determine whether washing the Nanosep® 
100K centrifugal filters prior to their use with plasma samples would improve the 
performance of the filtration device.  
 2 equine plasma sample were thawed at room temperature 
 To wash the filtration devices: 
o 500µl of millipore water was pipetted into the sample reservoirs 
of the filtration devices  
o The filtration devices were placed in a fixed-angle centrifuge rotor 
and spun at 14,000g for 10 minutes 
o  The water collected in the filtrate receiver was discarded 
o The wash procedure was repeated a second time 
  0.5ml of each plasma sample was pipetted into the sample reservoir of a 
washed filtration device  
 The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g for 30 minutes (in 5 minute increments) 
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When it was discovered the plasma was not passing from the sample reservoir through 
the omega membrane and into the filtrate receiver of the filtration device, these filters 
were discarded and the volume of sample to be filtered was decreased.  
 0.25ml of each plasma sample was pipetted into a sample reservoir of a 
washed filtration device 
  The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g for 25 minutes (in 5 minute increments) 
 Following centrifugation, the remaining fluids in the sample reservoirs 
and the fluid collected in the filtrate receivers of the filtration devices 
were each analysed using an FTIR spectrometer as detailed above (in 
subsection 2.3) with the following exceptions: 
o The remaining fluid in the sample reservoirs was diluted 1:1 with 
sterile saline before analysis with the FTIR spectrometer (as the 
plasma was not diluted prior to filtration)  
o Only 3 sample replicates were analyzed for each of the sample 
sections 
 
For each sample, visual examination and comparison of the residual fluid in the sample 
reservoir to the original un-filtered spectra indicated a large amount of albumin was still 
present within the sample. When the two spectra were displayed on the same graph, 
substantial overlap was still present and they exhibited a similar appearance, yet, mild 
changes were apparent indicating some compounds have been removed from the 
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filtered spectra.  However, spectra obtained from the filtrate fluid still displayed a weak 
signal, indicating that albumin had not been effectively removed from the sample. 
 
2.8 Second filtration trial using washed omega membranes 
 2 equine plasma sample were thawed at room temperature 
 Filtration devices were washed as outlined above (in subsection 2.7) 
 150 µl of each plasma sample was pipetted into the sample reservoir of a 
washed filtration device  
 The filtration devices were placed in a fixed-angle centrifuge rotor and 
spun at 14,000g in 5 minute increments until all fluid appeared to have 
filtered through the membrane (total spin time was 40 minutes) 
 250 µl of sterile saline was added to the sample reservoir which was then 
manually agitated in an attempt to reconstitute the immunoglobulins 
which should have remained on the filter 
 The fluids in the sample reservoirs and the fluid collected in the filtrate 
receivers of the filtration devices were then each analysed using an FTIR 
spectrometer as detailed above (in subsection 2.3) with the following 
exceptions: 
o The remaining fluid in the sample reservoirs was diluted 1:1 with 
sterile saline before analysis with the FTIR spectrometer (as the 
plasma was not diluted prior to filtration)  
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o Only 3 sample replicates were analyzed for each of the sample 
sections 
 One of the plasma sample was also diluted 1:1 with sterile saline (125µl 
serum + 125µl saline) 
 The diluted sample was pipetted into the sample reservoir of a filtration 
device  
 The filtration device was placed in a fixed-angle centrifuge rotor and spun 
at 14,000g for 20 minutes (in 5 minute increments) 
 Following centrifugation, the remaining fluid in the sample reservoir and 
the fluid collected in the filtrate receiver of the filtration device were 
each analysed using an FTIR spectrometer (as detailed above in 
subsection 2.3) 
 Following analysis with the FTIR spectrometer, all fractions obtained from 
the filtrate receivers in this filtration trial were analyzed using a 
commercial equine IgG RID assay (Kent Laboratories, Bellingham, WA) to 
assess whether any immunoglobulins had passed through the filter 
 
For each sample, visual examination and comparison of the residual fluid in the sample 
reservoir to the original un-filtered spectra indicated a large amount of albumin was still 
present within the sample. When the two spectra were displayed on the same graph, 
substantial overlap was still present and they exhibited a similar appearance, yet, mild 
changes were apparent indicating some compounds have been removed from the 
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filtered spectra.  However, spectra obtained from the filtrate fluid still displayed a weak 
signal, indicating that albumin had not been effectively removed from the sample. 
 
With the RID assays used in this filtration trail, no discernible rings of precipitation were 
identified for any of the fluid samples from the filtrate receivers. This confirms that no 
immunoglobulins had passed from the sample reservoir through the omega membrane 
and into the receiver of the filtration devices. 
 
 
